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Trivial names of pro s taglandins and their analogues have been used
throughout this thesis. The systematic names for some of the C20
prostanoids and analogues referred to in this thesis are shown below
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In drawing chemical structures stereochemistry is not implied but a
thickened or dotted line denotes a substituent located above or below the
plane of the paper respectively.
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ABSTRACT
This thesis describes attempts to characterize prostacyclin (IP) and
prostaglandin E (EP) receptors in smooth muscle preparations using
agonist potency ranking and susceptibility to receptor blockade.
Platelet aggregation is inhibited by prostacyclin analogues through
activation of IP-receptors present on the plasma membrane. This
potentially useful anti-thrombotic action is compromised by powerful
vasodilator activity. The relaxant activity of cicaprost, iloprost,
carbacyclin and EP157 (a novel prostaglandin endoperoxide analogue
which mimics prostacyclin in the human platelet) was measured on
isolated arterial rings from man, pig, rabbit and dog: Potency
decreased in the order given above and there was little evidence for
significant differences between the IP receptors in the different
preparations. In man the agonist potency at vascular IP sites
correlates well with that of the platelet thus presenting little hope for
separation of the two actions.
In addition, the IP receptor present in the guinea-pig ileum has been
investigated. This receptor is of particular interest as it has been
shown to mediate longitudinal muscle contraction via the release of
excitatory neurotransmitters from the myenteric plexus.
Only the action of cicaprost was abolished by morphine and
tetrodotoxin: PGI2, iloprost and carbacyclin were only partially
inhibited and the residual contraction in each case was abolished by the
EPi-receptor antagonist, AH6809. These results suggest a high degree
of selectivity for cicaprost. However, the analysis is complicated by the
discovery of an IP-receptor which inhibits longitudinal muscle
contraction (histamine in the presence of AH6809). Antagonist
investigations suggest that the excitatory transmitters released by IP-
receptor activation are Acetylcholine and Substance P.
Recently, the existence of three subtypes of the PGE receptor have been
proposed and pharmacological / chemical efforts have centred on the
characterization of these receptors and identification of their
physiological actions. A detailed study has been carried out comparing
the actions of eleven PGE analogues on three tissues containing EP3-
receptors.
(1) Guinea-pig ileum: In the absence of enteric nerve function this
tissue has previously been defined as EPi- selective. However, the
present studies suggest the presence of a second receptor mediating
contraction and this has some similarities to the EP3-receptor found in
the guinea-pig vas deferens. In particular sulprostone and MB28767
are highly active in the presence of AH6809.
(2) Chick ileum: Literature studies suggest the presence of an EP3-
receptor mediating contraction. The results obtained confirm this,
however, detailed study has revealed differences between agonist
activity in this tissue and the guinea-pig vas deferens, the most obvious
being the low maximum (~ 50% of that of PGE2) of the potent EP3
agonist, sulprostone.
(2) Rabbit jugular vein: This tissue has recently been shown to contain
PGD2 relaxant receptors however, the action of PGE2 has not yet been
studied. Investigations have shown that the preparation contains a
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highly sensitive EP2 receptor mediating relaxation (IC50<lnM).
However, the PGEi analogue, butaprost, appears to be considerably less
active than expected from data obtained in other preparations known to
contain EP2-receptors (guinea-pig trachea and cat trachea).
The rabbit jugular vein has previously been shown to contain a
contractile thromboxane (TP) receptor which is highly sensitive to the
thromboxane mimetic, U46619 (EC50 ~ 3nM). A number of PGE
analogues have potent thromboxane-like (TP-receptor agonist) actions
thus the above experiments were carried out in the presence of a TP-
receptor antagonist. Characterization of this receptor suggests that it






The first prostaglandin metabolites of arachidonic acid, discovered more
than twenty years ago, were the stable species PGE2 and PGF2a
(Bergstrom and Sjovall, 1960 a and b). Subsequently, Bergstrom (1966)
announced the structures of several naturally occurring
prostaglandins. They have since been shown to arise from unstable
intermediates, PGG2 and PGH2, the prostaglandin endoperoxides
(Hamberg et al, 1974). PGG2 and PGH2 also undergo enzymatic
transformation to unstable products, thromboxane A2 (TXA2) (Piper and
Vane, 1969; Hamberg and Samuelsson, 1974) and prostacyclin (PGI2)
(Moncada et al, 1976; Johnson et al, 1976).
Most mammalian cells can release prostanoids in response to various
stimuli including hormones, antigen challenge, thrombin and collagen
and mechanical trauma. They are synthesised from twenty carbon
polyunsaturated fatty acid constituents of membrane phospholipids.
Thus, dihomo-y-linoleic acid, arachidonic acid and eicosopentaenoic
acid form the 1-, 2- and 3- series prostanoids respectively (Samuelsson et
al, 1978; Moncada et al, 1980; Smith et al, 1985). Arachidonic acid is the
most abundant of these three precursors thus the 2- series
prostaglandins are formed almost exclusively in most mammalian
tissues (Moncada et al, 1980). Before prostanoid synthesis can take place
free, unesterified arachidonic acid must be released. Release (see
Figure 1.1) is catalysed by the phospholipase enzyme phospholipase A2
(PLA2) (Flower and Blackwell, 1976)." Although this pathway is thought
to be the most important (Mahadevappa and Holub, 1986), there is
evidence that in the human platelet, phospholipase C (PLC) may release
1,2-diacylglycerol from which arachidonic acid is liberated by
diglyceridelipase (Smith, ,1981).
After arachidonic acid is released from tissue stores, conversion into
prostaglandins and thromboxanes occurs in two steps (see Fig 1.2). The
first step is the formation of the prostaglandin endoperoxides which is
catalysed by prostaglandin endoperoxide synthetase (Needleman et al,
1986). The cyclooxygenase activity of the enzyme catalyses the formation
of a 15-hydroperoxy compound, PGG2, while the peroxidereactivity
2
Figure 1.1: Schematic representation of two enzymatic pathways
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Figure 1.2: Diagram showing the synthesis of the 5 natural


















reduces the hydroperoxy group to a hydroxy, giving PGH2. The second
step involves enzymes which are tissue specific and result in the
formation of products characteristic to a tissue such as thromboxane in
platelets (Ho et al, 1976; Ullrich and Haurand, 1976) and prostacyclin in
vascular endothelial cells (Gryglewski et al, 1976; DeWitt and Smith,
1983).
Nonsteroidal anti-inflammatory drugs, such as aspirin and
indomethacin, inhibit cyclooxygenase (Vane, 1971), and will therefore
prevent the formation of prostaglandin endoperoxides resulting in
decreased formation of the final products, the prostaglandins and
thromboxanes.
Since the discovery of prostaglandins they have been demonstrated to be
involved in a wide range of physiological systems including:
contraction/relaxation of smooth muscle, control of neurotransmitter
release, aggregation/antiaggregation of blood platelets, control of renal
function, structural and functional changes in the ovary, function of the
eye and gastrointestinal absorption and secretion. They have also been
implicated in the pathophysiology of a number of conditions such as
thrombosis, inflammation, asthma, cancer, pyrexia, migraine and
renal disease (see Coleman et al, 1990).
Horton (1969) was the first to suggest that discrete receptors for
prostaglandins may exist which could be distinguished from those of
other agonists by selective antagonists: their action was not blocked by
atropine, methysergide, mepyramine, propranolol, phenoxybenzamine
and hexamethonium. In addition, he suggested that "from the
qualitative and quantitative differences in the biological properties of
various natural prostaglandin families several different prostaglandin
receptors may exist". PGI2 and PGD2 differ from the other 2-series
prostanoids in that they potently inhibit platelet aggregation. Studies by
Miller and Gorman (1979) and Whittle et al (1978) provided evidence that
these prostanoids act via their own distinct receptors: (1) exposure of
platelets to high concentrations of PGI2 blocks the effects of subsequent
application of PGI2 but not PGD2 and vice versa (2) the antiaggregatory
action of PGD2, but not that of PGI2, is blocked by the phenyl
6
Table 1.1: Classification of prostanoid receptors in some isolated
smooth muscle preparations. Kennedy et al, 1982.








E2 > I2 = F2a > D2 = U 46619
E2 > I2 ^ F2a > D2 = U 46619
E2 > F2a > I2 > D2 > U 46619
E2 > I2 > F20C > D2 = U 46619
E2 > I2 > F2a > D2 = U 46619
F2a > D2 > U 46619 > E2 > I2




111 U 46619 » F20C > E2 = D2 = I2
U 46619 » D2 > I2 = F2a > E2
U 46619 » F2a > E2 > I2 > D2
phosphonate antagonist, N-0164. Kennedy et al (1982) studied the action
of PGE2, PGF2a> U 46619 (a thromboxane mimetic), PGI2 and PGD2 on a
wide range of preparations. The results showed that the preparations
could be divided into three groups on the basis of striking similarities in
the rank order of potency of the prostanoid. The authors proposed that
the very marked differences between the groups reflected the existence of
three distinct classes of prostanoid receptor (see Table 1.1) Thus, they
postulated that distinct receptors existed for each class of natural
prostanoids: PGD2, PGE2, PGF2a> PGI2 and TXA2 corresponded to DP,
EP, FP, IP and TP receptors respectively.
This thesis is chiefly concerned with the further characterisation of IP,
EP and TP receptors present in various smooth muscle preparations, a
range of agonists and antagonists has been used.
A range of basic pharmacological techniques have been employed to
classify these receptors.
The law of mass action is used to describe the binding of drugs to
receptors:
where Rt = total concentration of receptors, [AR] = concentration of drug
receptor complex, Ka = equilibrium dissociation constant for the
receptor.
Stephenson (1956) introduced the idea that the response to agonists was
not necessarily directly proportional- to the receptor occupancy. He
introduced the concept of stimulus (S) which assumed that the response
was some function of the stimulus.
Ea = Response to a given concentration of A, Em = Tissue maximal
response.
In addition, the parameter relating stimulus to occupancy was termed
'efficacy', (e):
[AR] = [A]
Rt [A] + Ka
f
8
In this definition efficacy was a drug and tissue dependent term. The
model was later modified by Furchgott (1966) who defined the term
intrinsic efficacy', (E ):
e = E [ Rt ]
In these terms intrinsic efficacy was strictly a drug related parameter
constant for given drug-receptor pairs across species and tissues.
Hence,
Ea = f IE [ Rt ] [A]
£M [A] + Ka
Thus, the tissue related factors are (1) f, the function relating stimulus
and response and (2) Rt, the total receptor concentration. And receptor
related parameters are (1) Ka, the equilibrium dissociation constant of
the drug for the receptor and (2) E, intrinsic efficacy.
If one assumes that Ka's for full agonists significantly exceed the
concentration required for response (Ka < [A]), then stimulus can be
given by S = E [Rt] [A] / Ka. Thus, in each individual tissue:
Sl = £^J and S2=WKa, Kaj
The potency ratio or equi-effective molar ratio (EMR) of these two full
agonists in producing equal responses (Si = S2) is:
FMR = [All =' E 2 [KAi]
m JTIkIS
This ratio reflects only the drug-receptor parameters, E and Ka, and is
independent of tissue factors. It can thus be used in the classification of
receptors.
It is notable that differences in receptor coupling may cause differences
in the position of the log concentration-response curves of full agonists
(those whose intrinsic efficacy is sufficient to produce a maximal
response) but not partial agonists (those with lower intrinsic efficacy).
Instead differences in receptor coupling will produce changes in the
9
maximal response of partial agonists but little change in the position of
the log concentration-response curve. Thus, in two different tissues
with identical receptors but different stimulus-response coupling a full
and partial agonist may have different potency ratios.
The potency of a competitive antagonist depends upon its equilibrium
dissociation constant (Kb) for the receptor. This is a chemical term
which is independent of receptor function, location and animal species.
Schild (1949) developed the pA scale in which pA2 defines the negative
logarithm of the molar concentration of antagonist which produces a
two fold shift to the right of a concentration response curve. Schild also
derived a useful equation to calculate the Kb of a competitive antagonist:
Log (dr-1) = nLog [B] - Log Kb
dr refers to the ratio of equi-active concentrations of agonists in the
presence and absence of antagonist, [B]. This equation predicts a linear
regression (Schild plot) with a slope of unity when a simple competitive
antagonist binds to a homogeneous population of receptors. The
resulting Kb under these conditions is a constant which reflects only
antagonist receptor interaction and is independent of the agonist used.
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department by N.H Wilson, C. Marr and G.M Muir.




Acid-Citrate dextrose (ACD) - ( A 120 mis distilled water)
3 g D-glucose B.D.H Chemicals
2 g Disodium Hydrogen citrate
*v.»ole. op Lo
Krebs ( A 5 litres distilled water)
10.5 g Glucose
10.5 g Sodium Hydrogen Carbonate
34.5 g Sodium Chloride
17.5 ml Potassium Chloride (10%)
7 ml Magnesium Sulphate (10%)
8 ml Potassium Dihydrogen Orthophosphate (10%)
12.6 ml Calcium Chloride (1 molar)
rwo.de. up
Tyrodes ( K 5 litres distilled water)
5 g Glucose
5 g Sodium Hydrogen Carbonate
40 g Sodium Chloride
10 ml Potassium Chloride (10%)
13 ml Magnesium Sulphate (10%)
2.5 ml Sodium Dihydrogen Phosphate (10%)
9 ml Calcium Chloride (molar)
*^c*.cAc. op to
Tris Buffer, pH 7.4 ( A 1 litre distilled water)
6.06 g Tris taken to pH7.4 with concentrated HC1.
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METHODS
ISOLATED SMOOTH MUSCLE PREPARATIONS
Guinea-pig ileum
Male guinea-pigs (300-500 g) were killed by a blow to the head followed by
exsanguination. The terminal portion of the ileum was excised after
discarding the 8-10 cm portion nearest the ileo-caecal junction. The
tissue was cleaned and kept in Tyrodes solution of the following compo¬
sition (mM): NaCl 136, KC1 2.7, CaCl2 1.4, MgCl2 0.49, NaH2P04 0.32,
NaHC03 12 and glucose 5. Segments of ~2 cm were mounted vertically
in 10 ml organ baths under 0.5 - 0.75 g tension. Changes in tension
were measured by means of a Grass FT03 isometric transducer
connected to a Grass polygraph recorder. The bath solution was bubbled
with 95% 02 and 5% C02 and maintained at 37°C. Bathing solution was
changed by upward displacement and overflow. The tissues were
allowed to equilibrate for ~1 hr prior to testing with a dose of 14 nM
PGE2.
Concentration-response curves to all agonists were non-cumulative and
drugs were added in 1, 3, 10, 30 or 1, 5, 10, 50 sequence. The
preparations were exposed to doses of drug for 30-60 seconds and a
minimum of 15 minutes was allowed between additions. Responses
were calculated as a % of the acetylcholine maximum obtained in each
preparation at the end of the experiment.
Effect of inhibitors
(1) Against single doses: Two control responses to the agonist were
established, the tissue was then exposed to the inhibitor 20 minutes
prior to addition of a third dose of agonist. The effect of the antagonist
was then expressed as a % inhibition of the control response (mean
value) and the % inhibition obtained from single preparations from 5
different animals averaged and s.e.m (standard error of the mean)
calculated.
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The differences in response levels before and after exposure to inhibitor
were tested for significance using an unpaired Student's t-test.
(2) Against concentration-response curves: Concentration-response
curves to any one agonist were established simultaneously in 2
preparations from the same animal, one of the tissues being bathed in
Tyrodes solution containing the blocker added 20 minutes prior to the
start of agonist addition. Dose-ratio was calculated as follows: EC25 in
the presence of inhibitor / EC25 in the absence of inhibitor. The ratios
obtained from experiments in 5 different animals were averaged and
s.e.m calculated. PD25 values (- log EC25 ) in the presence and absence
of the inhibitor obtained from single preparations were calculated and
the difference tested for significance using an unpaired Student's t-test.
Inhibition of histamine - induced contractions
Preparations were bathed in Tyrodes solution containing 1 |iM
morphine and 2 p.M AH6809. The tissue maximum was established
initially with 1.5 |iM histamine. Subsequently, each tissue was exposed
to a dose of histamine producing a contraction of -60% of the maximum
at 2 minute intervals. Inhibitors were added immediately after wash¬
out of histamine. The effect of the inhibitor was calculated as a %
inhibition of the control response to histamine.
Chick ileum
5-20 day old chicks were killed by decapitation. The dissection and
experimental procedure was identical to that used for the guinea-pig
ileum. The tissues were allowed to equilibrate for -1 hr prior to testing
with a dose of 14 nM PGE2.
Concentration-response curves to all agonists were non-cumulative and
drugs were added in 1, 3,10, 30 or 1, 5, 10, 50 sequence. The
preparations were exposed to doses of drug for 30-60 seconds and a
minimum of 15 minutes was allowed between additions. Responses are
calculated as a % of the acetylcholine maximum obtained in each
preparation at the end of the experiment.
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A concentration-response curve for PGE2 was carried out on one
preparation from each animal. The other preparations were exposed to
various test prostanoids and EMR values calculated in the following
way: EC25 of the test prostanoid / EC25 of PGE2 in preparations from the
same animal. EMR values from preparations from 5 different animals
were averaged and the s.e.m calculated. Similarly PD25 values for each
agonist were calculated averaged and the s.e.m calculated.
Effect of 'inhibitors '(AH6809, sulprostone and 'cocktail') : A cumulative
concentration-response curve for PGE2 was carried out on one
preparation. Following wash-out the 'inhibitor' was added and 10-20
minutes later a second concentration-response curve to PGE2 was
obtained. Control curves were obtained simultaneously in a separate
preparation.
Rabbit jugular vein
Male New Zealand White rabbits (2-4 kg) were injected with heparin
(1000 units) via the marginal ear vein prior to cervical dislocation and
exsanguination. The external jugular veins were removed, cleared of
fat and adherent connective tissue and cut into rings (-4 mm wide) by
transecting the vein. The rings were suspended between two hooks in a
10 ml organ bath containing Krebs solution (mM : NaCl 118, KC1 5.4,
CaCl2 2.5, MgS04 1.0, NaH2P04 1.1, NaHC03 25, glucose 10 and
indomethacin lpM) under a tension of 0.75 g. Changes in tension were
measured by means of a Grass FT03 isometric transducer connected to
a Grass Polygraph recorder. The bath solution was bubbled with 95% O2
and 5% CO2 and maintained at 37°C. Tissues were allowed a 1 hr period
of equilibration during which changes in the resting tension were
readjusted. All tissues were initially contracted with 10 pM histamine
to establish the tissue maximum.
EP receptor studies:
For investigation of the relaxant actions of prostanoids, stable tone levels
between 50 - 60 % of the maximum were obtained in all preparations
with -lpM histamine. Higher levels of contraction were subject to a
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considerable degree of fade. In order to block any thromboxane receptor
agonist action of the prostanoids tested, dose-response curves were
obtained in the presence of the TP receptor antagonist, GR 32191 (10gM)
(Lumley et al, 1987). Each preparation was exposed to two cumulative
series of PGE2 doses before testing a prostanoid analogue. The tissues
were allowed -30 minutes of frequent washing between cumulative
additions. Responses were calculated as the % inhibition of the
histamine-induced tone. PD50 values for each agonist were calculated
and those obtained from 5 different animals were averaged and the
s.e.m. calculated. Equi-effective molar ratios (EMR) were calculated in
the following way: IC50 for the analogue / IC50 for PGE2 (second curve)
in the same preparation. EMR from single preparations obtained from
5 different animals were averaged and the s.e.m. calculated.
TP receptor studies
Agonists: Two cumulative concentration-response curves for U46619
were obtained on each tissue before testing the TP-receptor agonists.
Tissues were allowed 30 minutes of frequent washing in between
concentration-response curves. Responses were calculated as a % of the
U 46619 maximum which was established in each preparation at the
end of the experiment. The PD50 values for each of the agonists were
calculated and those obtained from 5 different animals were averaged
and the s.e.m calculated. EMR values for each agonist were calculated
in following way: EC50 for the test compoud / EC50 for U 46619 (second
curve) in the same preparation.
Antagonists: The TP-receptor antagonists were added 20 minutes prior
to establishing a third concentration-response curve to U 46619. Dose
ratios were calculated as follows: EC50 for U 46619 in the presence of
antagonist / EC50 for U 46619 in absence of the antagonist. Dose-ratios




Rabbit superior mesenteric artery and was removed after
exsanguination of animals and placed immediately in Krebs solution
(as above). Pig gastro-epiploic artery was obtained after exanguination
of pigs (25-35 Kg) under Stesnil (20mgkg"1 intramuscularly) and
pentobarbitione (20mgkg_1 intravenous) anaethesia being used for other
purposes. Dog mesenteric artery was obtained from dogs under
pentobarbitone anaesthesia being used for other purposes. Human
mesenteric artery was obtained from patients undergoing gastro¬
intestinal surgery for a number of conditions. In all cases connective
tissue and fat were removed from apparently healthy sections of artery
and 4 rings (2-4 mm wide) obtained by transecting the artery. The rings
were set up in 10 ml organ baths for isometric tension recording by
Grass FT03 force displacement transducers coupled to a Grass
polygraph. Arterial rings were streched to an optimal tension of 1.5 g
and readjusted to this level throughout the equilibration period (1 hr).
All rings were initially contracted with 100 (iM phenylephrine (PE) to
establish the tissue maximum. Stable tone levels of 60-80% of the
maximum were obtained in all preparations with 1-3 pM PE.
Responses of the dog mesenteric artery to PE were more variable and
KC1, 10 or 15 mM, was used instead giving stable tone levels of 40-60 % of
maximum. On each preparation two cumulative concentration-
response curves to iloprost were obtained followed by one of the test
compound. Since experiments showed no change in the responsiveness
to iloprost between second and third exposures, equi-effective molar
ratios (EMR) were calculated from IC50 values for iloprost (second
curve) and the test compound. EMR derived from single preparations
obtained from 5 different animals were averaged and s.e.m. calculated.
Graphs
All graphs in this thesis show the arithmetic mean of responses. The




Blood was collected by venepuncture from a forearm vein of human
volunteers and mixed with -20% volume of acid citrate-dextrose
solution. The blood was then centrifuged at 250 g for 20 minutes. The
platelet rich plasma (PRP) was then transferred to a clean tube and 5-10
ng/ml of PGI2 added. A platelet pellet was prepared by further
centrifugation of the PRP at 450 g for 20 minutes. The supernatant
plasma was removed with a pasteur pipette before the pellet was
carefully resuspended in -50 mis of assay buffer (pH = 7.4): NaCl (100
mM), glucose (5 mM), Tris HC1 (50 mM) with indomethacin (1 jiM). The
platelet suspension was kept at 37°C until use.
Radioligand binding assay
The method used follows closely that of Narumiya et al (1986). Aliquots
of the platelet suspension (100 pi) were added to Eppendorf tubes which
already contained 0.02 pmol [125I]-PTA-OH (50 |il) and increasing
concentrations of the displacing agents (50 pi). Each displacer was
tested at six different concentrations in a 1, 3, 10, 30 etc. sequence and
each concentration was tested in triplicate. Each tube was incubated at
37°C for 30 minutes. In the experiments in which the displacing agent
was a TP receptor agonist, 4 nM cicaprost was included in the
incubation mixture in order to prevent aggregation. Three tubes
containing vehicle instead of displacing agent were also included, thus
allowing measurement of the total binding of the radioligand. An
additional three tubes contained 1 p.M ONO11120 - which was used to
determine the non-specific binding of the radioligand.
Following incubation, the tubes were centrifuged at 16,000 g for 1 minute
in a MSE 'Centaur 2' centrifuge, and the supernatant removed by
tapping the tube on absorbent paper. The pellets were then gently
washed with 1 ml of cold (0 °C) assay buffer, which was discarded and
any remaining solution removed from the tubes using a cotton bud. The
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radioactivity present in each tube was measured by a gamma counter
(LKB, Universal Gamma Counter).
Results
The displacement to each concentration of displacer is expressed as a %
of the maximum specific binding, calculated by subtraction of the non¬
specific binding from the total binding obtained in each assay. The data
was plotted as % specific binding versus log of the concentration of
displacer and the IC50 (concentration of displacer to cause 50%
inhibition of specific binding) calculated from the graph. The
relationship between IC50 and displacer Kd is given below
IC50 = _j£d
1 + [L]/Kl
Where L is the radioligand concentration and Kl is the dissociation
constant if the radioligand.
When [L] is « [Kl], then the IC50 of each displacer can be taken to
represent its Kd value. In this study this study the Kd of the ligand of
-20 nM (Mais et al, 1985a; Narumiya et al, 1986; Halushka et al, 1987) is
considerably higher than the ligand concentration of 0.1 nM.






Platelet and vascular actions
Moncada et al (1976) found that microsomal preparations of pig and
rabbit aorta and pig mesenteric artery transformed prostaglandin
endoperoxides into an unstable substance (then named PGX), which
differed from all currently known prostaglandins and thromboxanes (or
their metabolites). PGX was found to have potent platelet
antiaggregatory properties and relaxed strips of rabbit coeliac and
mesenteric artery (Bunting et al, 1976a and b). Subsequently, Johnson
et al (1976) elucidated the structure of PGX and it was renamed
prostacyclin (PGI2). Since then prostacyclin has been shown to be a
potent inhibitor of platelet aggregation (0.5-20 nM) in vivo in a wide
range of species (Sturzebecher et al, 1986). Prostacyclin elevates cyclic
AMP which in turn prevents platelet aggregation independently of its
effects on cytosolic free Ca2+ (Gorman et al, 1977). In human platelet
rich plasma (PRP), PGD2 and PGEi are 20 and 40 times less active than
PGI2 as inhibitors of aggregation (Whittle et al, 1978). Experiments
have shown that PGEi inhibits aggregation via the PGI2 (IP) receptor
while PGD2 has a distinct site of action (Whittle et al, 1978; Miller and
Gorman, 1979). In addition, PGI2 has been shown to dissaggregate
white thrombi in a system in which blood from animals or humans is
superfused over collagen strips (Bandt et al, 1984). When infused into
humans PGI2 reduces platelet aggregability, dissipates circulating
platelet aggregates and prolongs the bleeding time (Gryglewski et al,
1978; Szczeklik and Gryglewski, 1979). In addition, PGI2 has been
demonstrated to exert this anti-thrombotic action in many animal
models of venous and arterial thrombosis (Witt et al, 1986).
However, prostacyclin also has a potent dilatory action on vessels from a
number of species, and in vivo it causes a drop in systemic blood
pressure and reduces peripheral resistance by dilatation of arterioles.
In humans this action causes reddening of the face and neck and
unpleasant vascular headaches (see Whittle and Moncada, 1984).
In view of these two major actions of PGI2 recent chemical effort has
centred on the synthesis of chemically and metabolically stable PGI2
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Figure 3.1: Structure of PGI2 analogues and EP 157
Carbacyclin
COOH
analogues which retain the anti-thrombotic actions but have reduced
vasodilatory activity.
The chemical instability of PGI2 (Fig. 3.1) is due to the strained
enolether structure which can be protonated by the nearby carboxylic
function. Stabilization has been obtained by replacing the oxygen of the
enolether with a carbon, sulphur or nitrogen atom (Skuballa et al, 1987).
In carbacyclin (Fig. 3.1), the substitution is a carbon atom, and this
compound has been shown to be 3-10 times less active than PGI2 as an
inhibitor of platelet aggregation and in reducing systemic arterial blood
pressure in a number of species (Whittle et al, 1980). Further
modifications of the carbacyclin structure have been shown to produce
increased agonist potency at IP receptor sites on both platelet and vessel.
In iloprost (ZK 36374) (Schror et al, 1981) there is an additional single
methyl group at C16 and an acetylenic group at C18, and this compound
has been shown to be equipotent with PGI2 both as an inhibitor of
platelet aggregation and as a vasodilator (Casals-Stenzel et al, 1983).
Iloprost has also been shown to be orally active in man with a half-life of
20-30 minutes (Fitscha et al, 1987), however, in the clinical situation it
would be useful to have an even greater duration of action. The
relatively short half-life of iloprost is due to rapid metabolism, primarily
by B-oxidation of the upper side chain (Krause et al, 1984). The most
recent PGI2 analogue to be synthesized, cicaprost (Skuballa et al, 1986),
(Fig. 3.1) contains an ether oxygen in the 3 position to prevent B-
oxidation. In addition, increased potency has been obtained by: (a)
converting the 13,14 double bond into a triple bond (b) introduction of a
pure 16(S) methyl group and (c) addition of a further methyl group at
C20 (it is notable that unlike cicaprost, iloprost is a mixture (approx.
50:50) of 2 diastereoisomers epimeric at C16: Skuballa and Vorbruggen,
1983). Gicaprost (ZK 96480) has been shown to be 5-12 fold more potent
than PGI2 with respect to in vivo hypotensive and antiaggregatory
actions, with a duration of action of 5-48 hours (Mueller et al, 1984;
Sturzebecher et al, 1986).
There is no indication from the above studies that the IP receptor on the
platelet differs from that on blood vessels. However, Whittle and
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Moncada (1984) used a 'selectivity ratio' to give an indication of the
separation between antiaggregatory and vasodilatory actions of a series
of PGI2 analogues. They found that it was possible to lose platelet
activity while retaining vascular actions, and on this basis proposed
that there may be differences in the structural requirements for binding
to these sites. However, as pointed out by the authors the data have to be
interpreted with caution: they have compared in vivo (cardiovascular)
results with in vitro (platelet) and the data have been obtained from
different species (rat blood pressure vs human platelet).
Later studies have demonstrated that certain PGI2 analogues display
antagonist actions on the vasculature while retaining antiplatelet
(agonist) actions (Fassina et al, 1985; Corsini et al, 1987; Olivia et al,
1989). However, the interpretation of these results is called into question
by recent findings that a number of PGI2 analogues (iloprost and
carbacyclin) and indeed PGI2 itself, have significant EPi agonist activity
(Dong and Jones, 1982; Dong et al, 1986; Sheldrick et al, 1988; Lawrence
and Jones, 1988). EP receptors are known to mediate contractile
responses in a number of tissues and these may oppose any IP-mediated
relaxation via physiological antagonism.
There appears to be a need for comprehensive study of the actions of a
number of PGI mimetics in both the platelet and vasculature from a
range of species. We have investigated the relaxant action of iloprost,
cicaprost and carbacyclin in visceral arterial vessels in vitro from man,
pig, rabbit and dog and compared this to their antiaggregatory action in
platelets from the same species. Since iloprost appears, from the
literature (see Gryglewski and Stock, 1987), to be the most widely studied
PGI2 analogue it was used as the standard agonist. Any EP-mediated
contractile actions of the compounds could be assessed on the basis of (1)
the effect of the EPi-receptor antagonist, AH 6809 (Coleman et al, 1985)
(2) the fact that cicaprost has been shown to be highly selective for the IP
receptor with little EPi receptor activity (Dong et al,1986).
In addition, we have further investigated the actions of EP 157. Earlier
work (Armstrong et al, 1986) has shown that the endoperoxide
analogues, EP 157 and EP 035, behave as specific thromboxane receptor
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antagonists in isolated smooth muscle preparations which are
prostacyclin-insensitive (rabbit aorta, dog saphenous vein and guinea-
pig trachea). However, in human platelets EP 157 inhibits aggregation
induced by ADP, PAF and thromboxane, maximally activates
membrane-bound adenylate cyclase and displaces [3H] iloprost binding.
These actions suggest that the compound is an agonist at platelet IP
receptors - this is of particular interest in view of the fact that EP 157
bears little structural resemblance to PGI2 (Fig. 3.1). Thus, EP 157 has
been included in the study of vascular IP receptors.
Actions in gastrointestinal smooth muscle of the guinea-pig ileum
Like PGE2, prostacyclin (PGI2) is synthesised in the human and animal
intestinal tract (Bennet et al,1971; Whittle, 1981). As discussed above
PGI2 appears to be a relaxant agent in a range of vascular smooth
muscle preparations from different species. However, Gaion and
Trento (1983) have shown that PGI2 (1 nM-1 (iM) produces
concentration-dependent contractions of the longitudinal muscle of the
guinea-pig ileum. They found that at a concentration near the EC50 (20
nM), these contractions were abolished by TTX (10 nM), and inhibited by
atropine (1-30 nM) and hemicholinium-3 (20 pM). In addition, PGI2
potentiated electrically- induced contractions while having no effect on
the response to exogenous Ach. On the basis of these results they
proposed that PGl2-induced contractions are mediated by Ach released
from cholinergic neurones as a consequence of increased excitability of
the cell bodies (see Action of TTX). Further evidence for this
mechanism of action was presented by Gaion and Trento (1984b) in
finding that the action of PGI2 was inhibited by noradrenaline (30-300
nM), morphine (10-50 nM) and the purinergic receptor agonist N6-
phenylisopropyl adenosine (PIA) (10-50 nM). Noradrenaline,
enkephalins and adenine nucleotides have all been identified in
intestinal nerves of the guinea-pig and other species (Furness and
Costa, 1982), and are known to presynaptically modulate cholinergic
function (Paton and Vizi, 1969; Grintzler et al, 1975; Szerb, 1982; Moody
and Burnstock, 1982.).
However, these results appear to be at variance with earlier work
showing that PGI2 has a contractile action in the guinea-pig ileum in
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the presence of high concentrations of atropine (Moncada et al, 1976;
Kennedy et al, 1982), although under these conditions PGI2 appears to
be considerably less active (EC5o= 2.7 pM). Gaion and Gambaratto (1987)
later confirmed these results showing that in the presence of TTX (1
pM) or atropine (30 nM) 1 pM PGI2 retained 20-30% of its contractile
response. In addition, this response was unaffected by procaine or by
quercetin, although both drugs inhibited contractions in the absence of
TTX. There is evidence that procaine interferes with Ach release (Paton
et al, 1971) leaving the direct response to some agonists unaffected (Bury
and Mashford, 1976). This would also appear to be true for quercetin as
it was found to have no effect on direct contractions induced by Ach.
The authors suggest that at high concentrations, in addition to a
neuronal component, PGI2 has a direct contractile component of action
mediated by IP receptors present on the smooth muscle cells. However,
in view of the EPi agonist action of PGI2 demonstrated by Dong et al
(1986), an obvious explanation for the TTX/atropine-resistant component
of action would be a direct agonist action of PGI2 on the EPi receptors
known to be present in the guinea-pig ileum (see Chapter 4).
In view of the unique nature of this IP receptor linked to
neurotransmitter release we have investigated the action of a number of
PGI2 analogues in this system. The nature of the transmitters released
by IP-receptor activation has been studied using the muscarinic
receptor antagonist, atropine and the substance P receptor antagonist,
SP150. In addition, EPi receptor activity of these analogues was studied
using the EPi receptor antagonist, AH 6809.
Some details of the physiology of the guinea-pig ileum and the
mechanism of action of the compounds used to inhibit enteric nerve
function are given below:
Physiology
The gastrointestinal tract of the guinea-pig ileum consists of two muscle
layers and embedded between these two layers lies the enteric nervous
system. The majority of enteric neurones belong to the myenteric
plexus (Auerbach's), which lies just underneath the outermost muscle
layer of the gut wall, the longitudinal muscle, being sandwiched
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between this layer and the major gut muscle layer, the circular muscle.
The main role of these nerves is to bring about the ordered patterns of
contraction and relaxation seen during peristalsis.
The neurones of the myenteric plexus contain many neurotransmitters,
and neuromodulators including Ach, enkephalin, 5HT, VIP, substance
P, ATP, cholecystokinin, somatostatin, neuropeptide Y, galanin and
GABA (North, 1982; Jensen et al 1987). Evidence would suggest that
Ach is the major excitatory transmitter from the myenteric plexus of
the guinea-pig ileum to the cells of the longitudinal muscle layer (Paton,
1957) and also within the plexus (Nishi and North, 1973). Electrical
stimulation of the enteric nervous system leads to the release of several
substances (North, 1982), of which Ach is the most readily detectable
and the most widely studied (Szerb, 1982). In addition, peristalsis and
electrically-induced twitches of the guinea-pig ileum are inhibited to a
large extent by atropine (Kosterlitz and Lees, 1964 ; Hirst, 1979.).
However, there is also evidence that besides Ach, substance P (SP) is a
major excitatory transmitter in the gastrointestinal tract. SP occurs
within very large numbers of nerve processes and in about 5% of cell
bodies in the myenteric plexus (Furness and Costa, 1980). A role for SP
in peristalsis is most likely because there seems to be an arrangement of
SP neurones capable of maintaining propulsive motility in the presence
of atropine (Bartho and Holzer, 1985).
Action of morphine
It has been known for a number of years that morphine inhibits the
reflex peristaltic contractions and longitudinal muscle contractions of
the isolated guinea-pig ileum (Kosterlitz and Robinson 1957, Gyang et al
1964). Schaumann (1957) found that morphine decreases the
spontaneous release of acetylcholine (Ach) from the guinea-pig ileum
without inhibiting its synthesis or release from ground ileal tissue.
These observations led him to suggest that morphine reduces the
excitability of the neurones that release Ach - a conclusion which still
stands today. In addition, Paton (1957) showed that while morphine did
not affect the contractions of the tissue to Ach, it depressed twitches of
the tissue induced by coaxial stimulation. These early observations
have been confirmed by later electrophysiological studies. Extracellular
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recording has shown that morphine and enkephalin (1 nM-1 |J.M) will
inhibit firing of myenteric neurones, and almost all neurones tested
were sensitive to inhibition (North and Williams, 1977). Intracellular
recording from myenteric neurones has revealed that most cells are
hyperpolarised by morphine (North and Tonini, 1977). Furthermore,
the hyperpolarisation takes place primarily on the cell process - this has
been shown to prevent action potential propagation along the process of
the myenteric neurone (Morita and North, 1981).
While it has generally been thought that endogenous opioids inhibit
peristalsis and twitch of the electrically stimulated ileum by inhibiting
the release of enteric Ach, there is evidence that additional mechanisms
may be involved (Kromer and Schmidt, 1982). It has been shown that
effective peristalsis can be evoked in the presence of atropine and this
effect is abolished by the [Met] - enkephalin analogue FK33-842 (Bartho
et al 1982a). There is evidence that atropine-resistant contractions of the
guinea-pig ileum in response to electrical stimulation are mediated by
substance P: these have been shown to be inhibited by morphine (Bartho
et al, 1982b). In addition, Donnerer et al (1984) could only demonstrate
an appreciable release of substance P immunoreactivity during
peristalsis in the presence of naloxone. These results may reflect
-e-wi ftle.c4.sc. o(
modulation ofenteric substance P by opioids (Bartho and Holzer, 1985).
Action of TTX
TTX is known to block the passage of sodium ions through axonal
membrane channels, and as sodium currents are important in the
generation of action potentials TTX will block impulse conduction.
However, TTX is without effect on either the release of transmitter from
nerve terminals or the sensitivity of the post-synaptic membrane to the
transmitter (Narahashi, 1974). Hence, preparations treated with TTX





PGI analogues: Log concentration-response curves obtained on the
human mesenteric artery, pig gastro-epiploic artery, rabbit mesenteric
artery and the dog mesenteric artery are shown in Fig. 3.2. Sensitivity
to iloprost decreased in the order man, dog, rabbit, pig and cicaprost
was slightly more active than iloprost on all four preparations. EP 157
showed threshold relaxation at 20 nM in the human (Fig. 3.7A) and 200
nM in the dog, rabbit and pig (Fig. 3.7C). At the highest concentration
tested (6.7 pM) it gave relaxations of 70-95% of the iloprost maximum.
In the pig gastroepiploic artery, concentration-response curves to
carbacyclin were shallow reaching a maximum of -40% at 100 nM. At
concentrations above this carbacyclin produced discrete contractions of
the preparation (see Fig. 3.7C).
PGE analogues: In vessels from man, pig and rabbit PGE2 was highly
active as a relaxant, however in the pig and rabbit the curves reversed at
concentrations above 50 nM (see Fig. 3.3). 16,16-Dimethyl PGE2
contracted all three preparations; the pig vessel was considerably more
sensitive (EC50, 5 nM) than those of the human and rabbit (see Fig. 3.3).
Action ofAH 6809
AH 6809 (10 pM) slightly accentuated the relaxant action of PGE2 in the
rabbit mesenteric artery and inhibited the reversal of the curve (Fig.
3.4). However, in the pig vessels (Fig. 3.5) the blocker had no effect on
the concentration-response curve of carbacyclin or 16,16-dimethyl PGE2.
Action ofEP 092
In the pig EP 092 (1 |iM) caused a parallel rightward shift in the
concentration-response curve of U46619 consistent with a pA2 of 7.6.
However, this concentration of blocker had no effect on the
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Figure 3.2: Log-concentration response curves for relaxation of
(a) human mesenteric artery (b) pig gastro-epiploic artery
(c) rabbit mesenteric artery (means of 6-9 experiments) and
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Figure 3.3: Log-concentration response curves of (a) PGE2
(b) 16,16 dimethyl PGE2 for relaxation/contraction of visceral
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Figure 3.4: Effect of AH 6809 (10|iM) on log concentration-
response curves of PGE2 in the rabbit mesenteric artery
(mean of 2 expts.).
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Figure 3.5: The effect of AH 6809 on the log concentration-response
curves of (a) carbacyclin and (b) 16,16-dimethyl PGE2 in the pig



























Figure 3.6: Effect of EP 092 (lpM) on log concentration-response
curves of (a) U 466219 0)) carbacyclin and (c) 16,16 dimethyl PGE2
in contraction/relaxation of the pig gastro-epiploic artery





Firure 3.7A: Trace showing the relaxation of the human mesenteric
artery, precontracted with phenylephrine (2jiM), by (a) iloprost and
(b) EP 157.
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Figure 3.7B: Trace showing therelaxation of the rabbit mesenteric










Figure 3.7C: Trace showing the relaxation of the pig gastro¬
epiploic artery precontracted with phenylephrine (2pM) by




















Log concentration-response curves on preparations untreated with
antagonists/inhibitors are shown in Tig. 3.8. All the PGI analogues
tested acted as contractile agents, the rank order of potency being
cicaprost > iloprost > PGI2 > MMM-I-135 > carbacyclin. The curves for
cicaprost and MMM-I-135 reached a considerably lower maximum than
those of PGI2, iloprost and carbacyclin. In addition, the curve for
cicaprost appears to be bell-shaped, turning back on itself at
concentrations of greater than 10 nM.
Action of morphine and TTX
Single doses of the prostanoids: Morphine caused a dose-related
inhibition of responses to single submaximal doses (which gave
responses of 60-70% of the Ach maximum) of cicaprost, iloprost and
carbacyclin (Fig. 3.9). The action of cicaprost (13 nM) was abolished by
morphine (IC50 = 13 nM). The contractile action of iloprost (14 nM) and
carbacyclin (150 nM) could only be partially blocked by morphine ( 60%
and 30% respectively). At 1 pM TTX exhibited an identical profile of
inhibitory action to that of 1 pM morphine: the response to cicaprost was
abolished and that to iloprost and carbacyclin partially inhibited (Table
3.1). The effect of lOOnM on a single dose of cicaprost is shown in Figure
3.15A.
Concentration-response curves: Figure 3.10 shows the effect of
morphine on the log concentration-response curves of the prostanoids.
The curves of PGI2 and iloprost were subject to a significant shift in the
presence of 1 pM morphine. In addition, the log concentration-response
curve of iloprost appears to plateau at a maximum of 55-60%. In
contrast, the curve for carbacyclin was subject to a small shift which
was not statistically significant. In the presence of 1 pM morphine
cicaprost (see Fig. 3.15B) and MMM-I-135 were devoid of activity at
concentrations of up to 1 pM.
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Figure 3.8: Log concentration-response curves of (a) cicaprost and
MMM-I-135 and (b) iloprost, PGI2 and carbacyclin in the
guinea-pig ileum (means of 4-6 expts.).
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Figure 3.9: Log concentration-response curves for morphine
vs single doses of PGE2 (14nM), cicaprost (13nM), iloprost
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Table3.1:heffectofTX(lpM),Morphine(l )andAH6809(l M)ont r sponse















Figure 3.10: Effect of morphine (M) (lfiM) on the log concentration-
response curves of (a) PGI2 (b) cicaprost and MMM-I-135
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Action ofAH 6809
Single doses of the prostanoids: The response to a single dose of
cicaprost (13 nM) was unaffected by 1 pM AH 6809, however that to
iloprost (14 nM), carbacyclin (150 nM) and PGI2 (1 pM) were
significantly inhibited (Table 3.1).
Concentration-response curves: The presence of 2 pM AH 6809 in the
Krebs solution was found to greatly increase the spontaneous activity of
the preparation, making response measurements impossible, however,
the presence of morphine (1 pM) significantly reduced this effect.
Hence, concentration-response curves were obtained in the presence of
morphine (1 pM) and in the presence of morphine (1 pM) plus AH 6809
(2 pM), thus eliminating any neuronally-mediated action of the
prostanoids. AH 6809 caused a highly significant shift in the curves for
both iloprost and carbacyclin (Fig. 3.11). However, the log
concentration-response curves of iloprost did not appear to be parallel
and the dose-ratio obtained at the EC25 level (245) is -10 times greater
that found for carbacyclin.
Action ofatropine and SP 150
At a concentration of 200 nM atropine produced a dose ratio of 427
against Ach, consistent with a pA2 of 9.3 (Fig. 3.12). In the presence of
this concentration of atropine the concentration-response curve of
cicaprost appears to have a lower maximum, however, the EC50 values
(as calculated from the maximum of, each curve) are similar (see Fig.
3.15C). The concentration-response curves of iloprost and carbacyclin
were shifted to a similar extent as in the presence of 1 pM morphine
(Fig. 3.13).
Table 3.2 shows results demonstrating that at concentrations of 5 and 10
pM of the SP blocker appeared to be non-specific, inhibiting responses to
both SP (3 nM) and Ach (37 nM). However, at 1 pM SP 150 reduced the
response to a submaximal dose of SP by 91%, but had no effect on the
response to Ach. In addition, this dose of SP 150 significantly inhibited
(37%) the response to 13 nM cicaprost (Table 3.3).
Figure 3.11: Effect of AH 6809 (2gM) on the log concentration-
response curves of (a) iloprost and (b) carbacyclin in the
guinea-pig ileum (mean of 4-6 expts.).
log [Agonist] (M)
log [Agonist ] (M)
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Figure 3.12: Effect of atropine (200nM) on the log concentration-
response curves of Ach in the guinea-pig ileum (mean of 2 expts.).
log [Agonist] (M)
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Figure 3.13: Effect of atropine (200nM) on log concentration-
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Table 3.2: The effect of various concentrations of SP 150 on the response
to single doses of Ach, cicaprost, PGE2 and Substance P in the guinea-pig
ileum.
% INHIBITION
SP 150 ACh Cicaprost pge2 Substance P
concentration (37nM) (13nM) (14nM) (3nM)
10 |iM (n = 2) 50 100 60 100
5 |J.M (n = 2) 35 81 42 100
1 pM (n = 5) 0±0 37 ±6 22 ±5 98 ±2
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Table3.3:heffectofmorphine(1pM),Atr i(200nM)a dSP5(1M)





























Inhibition of Histamine-induced contractions
Cicaprost consistently caused a dose-related inhibition of contractions of
the ileum induced by sub-maximal doses of histamine (Fig. 3.14 and
3.15D), the IC25 obtained was 22 ± 3 nM. PGI2 and iloprost (see Figure
3.15D) also inhibited Histamine contractions. However, they caused an
initial contraction of the tissue prior to inhibition and the inhibitory
effect did not reach a maximum until several subsequent histamine
doses had been added. In a number of tissues (2/6 for iloprost and 2/5 for
PGI2) no inhibition was observed. In contrast, carbacyclin did not
inhibit histamine concentrations but instead potentiated these
responses.
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Figure 3.14: Log concentration-response curve of cicapost for
the inhibition of histamine -induced contraction of the guinea-pig
ileum (mean of 5 expts.).
60
Figure 3.15A: Trace showing contraction of the guinea-pig








Firure 3.15B: Trace showing the effect of morphine (l|iM) on
the contractile action of increasing concentrations of cicaprost




Figure 3.15C: Trace showing the effect of (a) atropine (200nM)
and SP 150 (lpM) and (b) SP 150 (lpM) on the contractile action
















Figure 3.15D: Trace showing the inhibitory action of increasing
concentrations of (a) cicaprost and (b) iloprost on contractions
of the guinea-pig ileum induced by histamine. The tissues were
















The results obtained with iloprost and cicaprost (Table 3.4) closely
parallel those obtained by Hadhzay (1986) who found that PGI2 relaxed
the human mesenteric artery with an IC50 of 7 nM and the sensitivity of
the mesenteric vasculature decreased in the order man, dog, rabbit, pig.
The data presented show that the human mesenteric artery is the most
sensitive preparation, with an IC50 of 1.2 nM for iloprost. Investigations
of the pig vasculature showed that the pulmonary, intralobular and
coronary arteries were not relaxed by PGI2, and the gastro-epiploic
artery was found to be the most sensitive vessel (iloprost IC50 = 24 nM).
It is possible that the true activity of the compounds at the IP-receptor
may be obscured/accentuated by agonist actions at additional prostanoid
receptor sites present on the smooth muscle. Table 3.5 shows the
vascular relaxant and contractile activity of PGE2 and 16,16-dimethyl
PGE2. In visceral vessels from the pig, man and dog PGE2 is highly
active as a dilator, the vessel from man being the most sensitive (IC50 =
0.27 nM). In general smooth muscle relaxation is thought to be
mediated by an EP2 receptor (Dong et al, 1986; Coleman et al, 1989), this
is supported by the finding that PGE2-mediated relaxation in the rabbit
mesenteric artery is not inhibited by the EPi receptor blocker, AH 6809.
However, previous work has shown that iloprost has little activity at
EP2-receptors in the guinea-pig and cat trachea (Dong et al, 1986;
Sheldrick et al, 1988). In addition, our studies suggest that iloprost and
carbacyclin have little activity at the EP2-receptor mediating relaxation
of the rabbit jugular vein (see Chapter 4). Thus, an agonist action of the
PGI2 analogues at the EP2 receptors of the arteries is unlikely.
There is, however, evidence for the presence of an EP-receptor
mediating contractile responses in these vessels: (1) In the pig and
rabbit the log concentration-response curve for PGE2-mediated
relaxation reverses at higher concentrations, and (2) 16,16-dimethyl
PGE2, which is highly active at EP1/EP3 receptors (Dong et al, 1986; see
Chapter 4) contracts all three preparations. In vessels from man and
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TABLE3.4:Relaxantactivityofpros cyclinmimeticsvis eralart ri lvessels. COMPOUND
Equi-effectivemolarrat o
Humanmesentericart ryPigga tro-epiploicrteryR bb tmes ntericrt ryDogm s nte ict ry
iloprost cicaprost carbacyclin EP157
1.0
(IC50=1.2±0.3nM) 0.36±08 9.6±1 5 220±46
1.0
(24±3nM) 0.87±0.17 (seet xt) 81±26
1.0
(10±InM) 0.53±0 2.1±0.2 230±32
1.0
(2.4±0.6nM) 0.46±03 3.6±0.04 898±134
Eachvalueisthemeanof6-9observationsinthum ,p gndrabbitvesselsd4-6itdove sel.
Table 3.5: Relaxant and contractile activity of PGE2 and 16,16 dimethyl
PGE2 in arterial vessels from the human, pig and rabbit.
PROSTANOID IC50/ EC50 (nM)
Human Pig Rabbit
PGE2 i- 0.27 12 >U
T>100 T>100
16,16 dm PGE2 *T 40 *t5 *T 30
■I Relaxation of Phenylephrine-induced contraction
T Contraction in the presence/*absence of Phenylephrine
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rabbit, 16,16-dimethyl PGE2 contracts the tissue at relatively high
concentrations (EC50 >30 nM) and there is no evidence that the PGI-
mimetics are acting on EP-contractile receptors. However, in the pig
gastro-epiploic artery, in which the EC50 for 16,16-dimethyl PGE2 is 5
nM, carbacyclin has a considerably lower maximum for relaxation
than iloprost and at concentrations above 100 nM it causes discrete
contractions. An opposing action of carbacyclin at contractile EP-
receptors may explain these results. In this preparation, the
concentration-response curves of carbacyclin and 16,16-dimethyl PGE2
are unaffected by AH 6809 indicating that the contractile receptor is not
EPi. It is notable that Ahluwalia et al (1988) have demonstrated EP3
mediated vascular smooth muscle contraction in the rabbit renal artery.
Experiments (Table 3.6 Jones, unpublished data) have shown that
carbacylin has EP3 agonist activity in the guinea-pig vas deferens,
although it is considerably less active than PGE2 (EMR, 70). The low
sensitivity of the pig vessel to relaxation induced by IP receptor agonists
may allow this contractile action to become apparent. An action of
carbacyclin at contractile thromboxane (TP)-receptors is excluded by the
failure of the TP-receptor blocker, EP 092 to affect the concentration-
response curve (Fig. 3.6).
PGI2 has previously been shown to have a weak contractile action in
vessels from the pig, human and rat (Dusting et al, 1977; Levy, 1978;
Davis et al, 1980); these effects are probably mediated by EP1/EP3
receptors. It is notable that when Rucker and Schror (1983) investigated
the binding of [3H]-iloprost to smooth muscle cells of the pig aorta they
found that the Hill plot was linear with a slope of 1.9. The authors
presented two possible explanations for this: (1) positive cooperativity
with two agonists binding to the same site and (2) the ligand binding to a
component other than the IP-receptor. The data presented here would
suggest that the PGI2 analogue may have bound to an EP1/EP3 receptor.
Invoking the above explanation for the low maximum of carbacyclin in
the pig, the data suggest that the IP-receptors present in vessels from
man, pig and rabbit are the same. In these tissues the order of potency
is cicaprost, iloprost, carbacyclin, EP 157. EP 157 relaxed at
concentrations 100-200 times that of iloprost. However, in the dog
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Table 3.6: pDso values for PGE2, cicaprost, iloprost and carbacyclin for
contraction of the guinea-pig trachea and for inhibition of the twitch
response of the guinea-pig vas deferens (mean of 4 expts.).
prostanoid Guinea-pig vas deferens Guinea-pig trachea
PD50 emr PD50
pge2 8.76 ± 0.03 (1)
cicaprost < 6.0 (>500) < 6.0
iloprost 6.79 ± 0.09 (88) 8.08 ± 0.13
carbacyclin 6.96 ± 0.12 (70) 7.57 ± 0.10
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TABLE3.7:Comparisonoftheabilitiesfprostacyclinmim ticstinh bitaggregationndtra elicAMP levels(bracketedvalues)inplateletsfromdiff r ntsp cies(Arms rongl,1989). Equi-effectivemolarconcen rations ProstanoidHumanP gHorseR bbita iloprost1.01.0 IC5o=0.15±0.042.30.8nM * cicaprost0.88±061.10.26 (1.0)(1.20) carbacyclin31±613.5+6.7 (23)(27) EP15754±9101±23* (72)(>1100)1.01.0. 23nM17.1±2.6nM4 71.5nM 0.41.3±0.210 6±0.09 (1.0)(0 91)(0.96) 153.3±0.43.5±0.5 (5.8)(2.9)( .7) 9890±210*35 015 0* (57)(>890)(>13 0)
mesenteric artery, although the order of potency is the same as that
found in the other vessels, EP 157 was 900 times less active than iloprost.
Similar results were found in initial studies by Armstrong and Jones
(unpublished observations) on anaesthetized dogs in which changes in
arterial blood flow were recorded in response to close intra-arterial
infusion of different prostanoids: iloprost was a highly active dilator but
EP 157 had no effect. Taken together these results suggest that the IP
receptor present in the dog vasculature may differ from that present in
the other species. However, no work has been done to investigate the
vasodilator activity in vivo of EP 157 in the other species.
As discussed in the introduction the emphasis of recent
chemistry/pharmacology has been on synthesis of a PGI2 analogue
which retains antiaggregatory actions but has reduced vascular
activity. However, in this study the order of activity of EP 157 in the
vasculature closely parallels that found on the platelet (Table 3.7) of the
same species (man, pig and rabbit) (Armstrong et al, 1989), suggesting
that the IP- receptors present in the two systems are the same. This
finding seems to leave little hope for separation of the two effects in
man. However, the possibility of partial agonism at the platelet IP
receptor has been demonstrated (Armstrong et al, 1989). It may be that
a compound with lower efficacy and higher affinity than EP 157 could
suppress platelet aggregation while having little effect on the
vasculature.
Guinea-pig ileum
We have confirmed the findings of Gaion and Trento (1983) indicating
the presence of a neuronal PGI2 receptor in the guinea-pig ileum: the
contractile action of PGI2 is inhibited by morphine and appears to be
mediated by activation of the enteric neurones. The results obtained are
summarised in Table 3.8. All the PGI2 analogues tested were active as
contractile agents, and the responses to single submaximal doses of
cicaprost, iloprost and MMM-I-135 were significantly reduced by both
morphine and TTX, indicating that they are agonists at the neuronal
IP-receptor site. However, only the responses to cicaprost and MMM-I-
135 were abolished by morphine; in the presence of 1 pM morphine
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Table3.8:PD25valu sforPGI2ana oguesithguinea-pigile mt bs ncendp e nce ofmorphine(1|iM)andAH68092(i )( eanf4-6xpts. . PROSTANOIDM XpD25p 25p 25 (%Ach)MORPHINEAH6809 (l|lM)(2(lM) cicaprost70+8.89±0.11<6 iloprost85+7.62±0.128. 50.065.96±0.12 carbacyclin80±57.720.08. 90 146 5± .11 PGI295±28.120 086.9917 MMM-I-135608.0±0. 8<5.89
concentration-response curves to PGI2, iloprost and carbacyclin could
be obtained.
The longitudinal muscle of the guinea-pig ileum contains both EPi and
EP3 receptors mediating contraction via a direct action on the smooth
muscle cells (see Chapter 4). Investigation of the effect of AH 6809 on
the action of the PGI2 analogues suggests that the morphine-resistant
component of action of the PGI2 analogues is mediated by an EP
receptor: (1) the responses to single submaximal doses of PGI2, iloprost
and carbacyclin are significantly inhibited by 1 pM AH 6809 and (2) the
concentration-response curves of these compounds are subject to a large
shift in the presence of 2 pM AH 6809. We have found PGI2, iloprost and
carbacyclin to contract the guinea-pig trachea, a preparation known to
contain EPi receptors. Although they appear to be more selective for the
EPi-receptor, the compounds also have some activity on the EP3
receptors of the chick ileum and the guinea-pig vas deferens (Table 3.6).
These results parallel earlier findings on the actions of PGI2 and
iloprost on EPi and EP3 receptors (Dong et al, 1986; Sheldrick et al, 1988).
As mentioned in the introduction Gaion and Gambaratto (1987) found
that at 1 pM PGI2 retains a contractile action in the presence of TTX.
They suggest that this is mediated by an IP-receptor present on the
smooth muscle. However, our data indicates that the TTX/morphine -
resistant component of action of PGI2 is more likely to be due to
activation of EPi (and perhaps EP3) receptors. The complete inhibition
of the contractile action of cicaprost by 1 pM morphine confirms the
work of Dong et al (1986) demonstrating that it is a highly selective IP-
receptor agonist. MMM-I-135 would appear to be less active at, but
equally selective for the IP receptor.
Further investigations of the nature of the excitatory transmitters
released in the response to neuronal IP receptor activation revealed that
the action of cicaprost is only partially inhibited by atropine (Table 3.9).
It may be that it is easier for atropine to block the effects of exogenous
Ach than that released from the myenteric plexus. For example, it has
been shown that considerably higher doses of atropine were required to
inhibit the response to cholinergic transmission in response to nerve
stimulation than those needed to inhibit the response to exogenously
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Table 3.9 : The effect of Morphine (1 |iM) and Atropine
(200 nM) on the concentration-response curves of PGI2
analogues in the guinea-pig ileum (mean of 4-6 expts.)..
PROSTANOID DOSE RATIO IN THE PRESENCE OF:
Morphine Atropine
(1 pM) (200 nM)
PGI2 18.9 ± 5 ***
cicaprost >1000 4.2 ± 2 *
iloprost 3.5 ± 1.2 * 4.4 ± 0.73 *
carbacyclin 1.6 ± 0.5 1.9 ± 0.32 *
MMM-I-135 >200
*** P < 0.001
* P < 0.05
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added Ach (Bowman et al, 1968). Alternatively, cicaprost may be
mediating the release of an additional transmitter whose action is not
blocked by atropine but whose release is blocked by morphine. The data
would suggest that the residual action of cicaprost is mediated by
release of substance P: the substance P blocker, SP 150 abolished the
response to cicaprost in the presence of 200 nM atropine.
Pharmacological (Franco et al, 1979a and b) and immunological
evidence (Donnerer et al, 1987) suggest that Ach or the ganglionic
stimulant DMPP are capable of stimulating the intrinsic SP neurones of
the intestine. While there is also evidence for the ability of SP to release
Ach from the myenteric plexus (Yau et al, 1982 ; Bartho and Holzer,
1985). However, our data show that both atropine and SP 150 inhibit the
response to cicaprost, and their action appears to be additive, thus it
would appear that IP- receptor activation mediates the release of both SP
and Ach.
It has been shown by a number of groups (see 'Action of morphine' )
that the release of both Ach and SP is inhibited by morphine. This
appears to be true in this system where neither transmitter is released
in the presence of 1 (iM morphine. In fact, Bartho and Holzer (1985)
stated that "among the drugs and procedures that influence SP release
there is not one which would not influence the release of Ach in the
same direction". It has been proposed that the similarities in the
pharmacological profiles of enteric cholinergic and SP neurones is due
to their co-localization in the same enteric neurones (Furness et al,
1984). It is notable that it has previously been suggested that SP release
from nerve endings could be implicated in the algesic response to both
PGEi and PGI2. Nakamura and Smith (1988) reported that the
inflammatory hyperalgesic response to both prostanoids was mimicked
by SP and inhibited by a SP antagonist.
The fact that the log concentration-response curve for cicaprost is bell
shaped (Fig 3.8) prompted us to investigate the activity of the compound
as an inhibitory agent. Fig.3.15D shows that cicaprost causes a dose-
related inhibition of histamine-induced responses, occurring at doses
corresponding to those at which the log concentration-response curve
bells. These results suggest that the preparation contains an additional
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IP-receptor present on the smooth muscle (any neuronal activity is
inhibited by the presence of lpM morphine), which mediates inhibitory
responses.
PGI2 and iloprost also inhibit histamine responses, however, the results
are inconsistent. Although these experiments were carried out in the
presence of 1 pM morphine and 2 pM AH 6809, in some preparations
there is evidence of an increase in tone prior to inhibition. This is
probably due to an EPi (overcoming the block) and/or and EP3 action of
these compounds and makes it difficult to assess the level of inhibition
obtained with these compounds. It is notable that the shift in the
concentration-response curve of iloprost in the presence of 2 pM AH
6809 (Dose ratio = 249) is considerably larger than that of any other PGE
(Dose ratio against PGE2 is 34, see following Chapter) or PGI analogue
tested. This may reflect a high EPi-selectivity of this compound,
however, it seems more likely that the shift is accentuated by the agonist
action of high concentrations of iloprost at IP-relaxant receptors. In
contrast, carbacyclin does not display any inhibitory actions but rather
contracts the tissue thus potentiating histamine-induced responses. As
found in the pig gastro-epiploic artery this is probably due to an agonist
action of this compound at contractile EP1/EP3 receptors opposing any
inhibitory effects mediated by IP-receptors.
A schematic representation of the IP receptors found in the longitudinal
muscle of the guinea-pig ileum is shown in Figure 3.16. Taking into
account the EP receptor activity of the analogues, the data presented
shows that the EMR values obtained are similar at both the neuronal
and the smooth muscle IP-receptor sites. Thus, there is no evidence to
suggest that these sites differ from one another or from those found on
the vasculature of the human, pig or rabbit.
Structure-Activity Relationships
The results presented confirm the finding that the introduction of a CH3
group at the C16 position of the carbacyclin molecule enhances the
potency of the compound at all the IP-receptor sites investigated. As
mentioned in the introduction iloprost used in this study contains both
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Figure3.16:SchematicrepresentationofIPrecept rsit snthguinea-pigl m TTX Morphine
Atropine SP150
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the 16(R) and the 16(S) isomers (Figure 3.17). However, Tsai et al (1988)
have recently demonstrated that the 16(S) isomer was 20-times more
potent than the 16(R) isomer in inhibiting collagen-induced platelet
aggregation. In addition, study of the binding of the isomers to platelet
membranes demonstrated that the 16(S) isomer had a significantly
higher affinity for the site than the 16(R) isomer (K^ = 13 nM and 288 nM
respectively). The authors suggest that the (S) methyl group limits the
flexibility of the molecule which facilitates the binding and allows close
interaction of the functional groups of iloprost with the IP receptor site.
These results have recently been confirmed in experiments by Imaki et
al (1989). They synthesised carbacyclin and 6-keto PGEi (an IP receptor
agonist - Hoult and Moore, 1986) with an alkyl cyclopentane ring on the
0) chain in which there are two new chiral centres at C16 and C18 and
found that the 16(S) isomers of both compounds were considerably more
potent than the 16(R) isomer in both platelet and blood vessel. In view of
these findings it would be of interest to investigate whether the IP
activity of these compounds is confined to the 16(S) and the EP1/EP3 to
the 16(R) isomer.
The potency and specificity of cicaprost for the IP receptor may therefore
be due to: (a) the introduction of a pure 16(S) methyl group (Figure 3.17)
and (b) further restriction of side chain movement conferred by the
13,14-acetylenic bond. While MMM-I-135 appears to retain the
specificity of cicaprost due to the 13,14 acetylenic bond, the absence of the
CH3 group at C16 may account for the lower potency of the compound.
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Prostaglandin E (PGE) was first isolated by Bergstrom (1966) in a pure
crystalline form from sheep prostatic glands. Since their discovery,
prostanoids of the E series have been shown to have activity in a range of
smooth muscle systems. They are known to be potent vasodilators in
most vascular beds (Holmes et al, 1963; Horton, 1963 and 1965;
Bergstrom et al, 1965; Euler, 1966; Nakano and McCurdy, 1967; Hatano
et al, 1980), and more recently PGE2 has been shown to constrict
vascular smooth muscle (Hatano et al, 1980 and 1981; Hayashi et al,
1986; Ahluwalia et al, 1988; Baxter et al, 1989). PGE also mediates both
relaxation and constriction of respiratory and uterine smooth muscle
(Horton, 1969; Apperley et al, 1979; Gardiner and Collier, 1980; Coleman
and Kennedy, 1985; Coleman et al, 1989). Finally, PGE has potent
actions in the gastrointestinal tract: in general it relaxes circular and
contracts longitudinal smooth muscle (Horton, 1965; Bennet et al, 1968;
Bennet et al, 1975).
In addition to their actions on smooth muscle, PGEi and PGE2 can both
inhibit and promote neurotransmitter release in a number of tissues
(Ehrenpreis et al, 1973). They are potent inhibitors of gastric acid
secretion in many species (Karim et al, 1973; Konturek et al, 1976;
Frame and Main, 1980; Broughton-Smith and Whittle, 1981; Reeves et
al, 1988) and have a range of actions on both the eye and the kidney
(Pederson, 1975; Bentley and McGahen, 1982; Remuzzi et al, 1987).
Prostaglandins of the E series have also been implicated in the
pathophysiology of a range of conditions including: inflammation
(Lewis, 1983); rheumatism (Moilanen et al, 1987); pain (Deraedt et al,
1980; Ferreira, 1983); cancer (Bennet, 1983) and pyrexia (Milton and
Wendlandt, 1971).
PGE receptors (see Table 4.1a and 4.1b)
Bennet and Posner (1971) first suggested that subtypes of the PGE2
receptor may exist. They showed that the dibenzoxazepine SC 19220
(Figure 4.1C) blocked the contractile action of PGE2 on the longitudinal
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TABLE 4.1b: Previous work on EP receptor sites in various tissues.
GPT= guinea-pig trachea (* 16,16 dimethyl PGE2 = standard agonist),
RSF=rat stomach fundus, CT= cat trachea,GPVD= guinea-pig vas
deferens, RGAS= rat gastric acid secretion, Chl= Chick ileum, GPF=
Guinea-pig fundus.
NA = not active and p.a = partial agonist.
References (Bracketed):
(1) Dong et al (1986) (6) Eglen and Whiting (1988)
(7) Gardiner (1986)
(8) Sheldrick et al (1986)
(9) Kennedy et al (1982)
(2) Coleman et al (1988)
(3) Reeves et al (1988)
(4) Coleman et al (1987a)
(5) Coleman et al (1987b)
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circular muscle was unaffected. More recently, it has been shown that
SC 19220 blocks PGE2-induced contractions of the guinea-pig ileum,
guinea-pig and dog fundus and the guinea-pig trachea in a competitive
manner (Kennedy et al, 1982; Coleman and Kennedy, 1985), whereas
PGE2-induced contraction of the chick ileum and relaxation of the cat
trachea are not inhibited. These results are the basis for the
classification of PGE2 receptors into EPi (blocked by SC 19220) and EP2
(unaffected by SC 19220).
In 1985, Coleman et al reported on a compound with an identical profile
to SC 19220 although 10-40 fold more potent as an EPi antagonist. They
found that AH 6809 (Figure 4.1C) was a specific competitive prostanoid
antagonist (pA2 6.8) on those preparations thought to contain EPi
receptors (guinea-pig ileum longitudinal muscle, guinea-pig fundus
and dog fundus), but weak or inactive (pA2 <5) on those containing EP2,
FP or TP receptors (cat trachea chick ileum, dog iris and guinea-pig
lung respectively).
Using agonists, Coleman et al (1987a) produced further evidence for this
subdivision: the PGE2 analogue, sulprostone was found to be highly
active as a contractile agent in the guinea-pig longitudinal muscle but
inactive as a relaxant in the cat trachea. This pattern was reversed for
the PGEi analogue, AY 23626. Similarly, Dong et al (1986) compared the
contractile and relaxant activity of a number of PGE analogues on a
range of preparations. They found that in the bullock iris sphincter, rat
stomach fundus, and the guinea-pig" trachea ICI 80205 and 16,16-
dimethyl PGE2 where more active as contractile agents than PGE2,
whereas, for relaxant action on the cat trachea, guinea-pig trachea and
dog hind limb arterial vessels in vivo the order of potency was reversed.
In contrast, 11-deoxy PGEi exhibited greater relaxant than contractile
potency when compared to PGE2.
Studies by Coleman et al (1987b) on sulprostone and AY 23626 lead to a
further subdivision of PGE2 receptors. On studying their action on the
chick ileum and the cat trachea (both contain receptors resistant to
block by AH 6809) they found that AY 23626 was active in both
preparations (EMR of 5.5 and 1.2 respectively). However, sulprostone
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was >9000 times less active than PGE2 in the cat trachea. They proposed
the existence of a subgroup of EP2 receptors to be known as EP3, upon
which sulprostone is highly active. Similar results were reported by the
group on comparing the action of sulprostone on the guinea-pig vas
deferens and the guinea-pig ileum circular muscle (Coleman et al
1987c). Again, sulprostone was found to be highly active on one
preparation (as an inhibitor of twitch in field stimulated guinea-pig vas
deferens) and inactive on the other (relaxation of the guinea-pig ileum
circular muscle). The agonist activity of PGE2 on both preparations was
unaffected by SC 19220 (300 pM) or AH 6809 (10 pM). More recently,
Reeves et al (1988) reported investigations of the activity of various
prostanoids as inhibitors of histamine-induced acid secretion in rat
isolated gastric mucosa. The rank order of agonist potency was very
similar to that found on the guinea-pig vas deferens and the action of
sulprostone was unaffected by 300 pM SC 19220. The authors proposed
that the effects were mediated by an EP3 receptor.
In this thesis the actions of PGE2 and a range of PGE analogues have
been investigated in three smooth muscle preparations. There are two
primary aims of the study: (1) to further characterise the receptors
present in these preparations and assess the usefulness of the tissues in
future study of EP receptor subtypes and (2) to study the
selectivity/specificity of a range of analogues and comment on their use
in the classification of EP receptors.
Tissues investigated
Chick ileum
As discussed earlier the chick ileum and the cat trachea were initially
thought to contain EP2 receptors as PGE2-induced relaxation was not
blocked by SC 19220 (Kennedy et al, 1982). However, subsequent
research has shown that sulprostone is active in this preparation but
devoid of relaxant activity in the cat trachea (Coleman et al, 1987b).
Thus, the receptor mediating contraction of the chick ileum has been
defined as EP3. Initial results in the guinea-pig vas deferens indicate




Previous work has shown that the rabbit jugular vein (RJV) contains a
number of receptors for non-prostanoids: adrenaline, bradykinin and
histamine (Kenakin, 1984).
More recently, the existence of prostanoid receptors in this tissue has
been investigated. Giles et al (1989) found that the thromboxane
mimetic, U 46619 contracted the preparation with an EC50 of ~6 nM.
The concentration-response curve of the compound was subject to a
parallel rightward shift in the presence of the thromboxane blocker, BM
13.177, consistent with a pA2 of 6.01 ± 0.01.
This group also investigated the relaxant actions of PGD2 against
histamine-induced contractions. In the absence of BM 13.177, the
concentration-relaxation curve for PGD2 was bell shaped - contractions
being produced at concentrations of >100 nM. In the presence of 30 pM
BM 13.177, PGD2 displayed only inhibitory responses with a IC50 of -80
nM. The relaxations induced by PGD2 and the PGD2-mimetic, BW
245C, were blocked by the potent DP-receptor antagonist, BW A868C.
However, both compounds displayed a phase of relaxation which was
resistant to the antagonist, and this effect was not blocked by the EPi-
receptor blocker, AH 6809. On the basis of these results the authors
suggested that the BW A868C-resistant relaxation may be mediated by
an EP2 receptor.
We have further investigated the possibility that the rabbit jugular vein
contains EP2 receptors, investigating the relaxant activity of PGE2,
PGEi, PGI2 and a range of their analogues.
Guinea-pig ileum - longitudinal muscle
Prostaglandins have been found in the gastrointestinal wall of man and
many other animals including the guinea-pig (Ambache et al, 1966). It
has been shown that both PGEi and PGE2 (2-500 nM) contract the
longitudinal muscle of the guinea-pig ileum in a concentration
dependent manner. These contractions are unaffected by hexa-
methonium but partially blocked by tetrodotoxoin (TTX), hyoscine and
atropine (Horton, 1965; Bennet et al, 1968.). In view of these results it
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was suggested that prostanoids stimulate two sites in the longitudinal
muscle: intrinsic cholinergic nerves and smooth muscle cells (Bennet et
al, 1968). Further evidence for a neural component of the action of PGE2
was found in experiments involving the use of morphine (see Chapter 3
- Introduction). Sanner (1971) demonstrated that 0.26 |iM morphine
produced an inhibition of the contractile response to PGEi (60%) and
PGE2 (41%). He noted that "prostaglandins have the potential for
producing part of their stimulatory effect by way of the intrinsic nervous
system. Whether this action is seen under physiological conditions is
open to conjecture".
A number of attempts have been made to measure the effect of PGE2 on
Ach release in the isolated guinea-pig ileum longitudinal muscle.
Hadhzay et al (1973) and Illes et al (1974) found that PGE2 in
concentrations up to 50 nM had no effect on Ach release. However,
Kadlec et al (1978) reported data showing that PGE2 caused a significant
increase in Ach release at low concentrations (6 nM). The discrepancy
may be explained by the finding that the ability of PGE2 to increase Ach
was inversely proportional to the initial output (Kadlec, 1978). Yagasaki
et al (1981) demonstrated the release of Ach from Auerbach's plexus by
PGEi, this action was inhibited by TTX.
A physiological role for PGE2 in cholinergic transmission has been
postulated on the basis of experiments investigating the effect of the
cycloxygenase inhibitor, indomethacin on electrically-induced
contractions of the tissue. Ehrenpreis. et al (1973) demonstrated that
indomethacin inhibited electrically-induced contractions of the ileum,
although the very high concentration used (111 pM) has been
subsequently shown to have non-specific inhibitory effects on Ach and
histamine contractions (Bennet et al, 1975). However, using a modified
Krebs solution a number of groups have demonstrated an inhibitory
action of lower concentrations (1-3 (iM) indomethacin on electrically-
induced contractions, which could be reversed by PGE2 (Kadlec et al,
1974; Bennet et al, 1975; Poll et al, 1988 a and b).
In order to show unequivocally that PGE has a physiological role in
mediating cholinergic transmission in the guinea-pig ileum one should
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measure the degree of synthesis inhibition and the degree of twitch
inhibition simultaneously in each tissue. Also, the action of a number
of structurally distinct cyclo-oxygenase inhibitors should be compared.
Botting and Salzmann (1974) found that 2.8 }iM indomethacin caused a
significant inhibition of PGE output both at rest and during field
stimulation, however it had no effect on Ach output during field
stimulation. In addition, Hedqvist et al (1980) demonstrated that PGE2
enhanced the contractile responses of the ileum to nerve stimulation,
Ach and direct muscle stimulation. However, the author concluded
that this was due to a postsynaptic potentiating action as PGE2 had no
effect on the release of Ach during field stimulation.
EP-receptors present: Kennedy et al (1982) investigated the action of
various prostanoids in the guinea-pig ileum in the presence of atropine,
indomethacin and phenoxybenzamine, thus restricting their action to a
direct one on smooth muscle cells. They found that SC 19220 (30-300 |iM)
caused a dose-related parallel rightward shift in the concentration-
response curves of PGEi, PGE2 and PGF2a- In addition, PGI2 was
almost 100 times less active than PGE2, while PGD2 and the
thromboxane mimetic, U 46619 were found to be inactive. On the basis
of these results they defined the guinea-pig ileum as an EPi-selective
preparation. More recently, AH 6809 has been shown to antagonise the
contractile action of PGE2 in this tissue (Coleman et al, 1987a). The
neuronal EP receptor has never been fully characterised. Recent work
by Poll et al (1988a and b) (see discussion) suggests that this receptor
may be a subtype other than EPi. Finally, Gardiner (1986) found that
high concentrations (3-10 gM) of butaprost (which the authors have
proposed to be EP2-selective agonist) caused a non-competitive inhibition
of histamine-induced contractions of this preparation. They proposed
the existence of an additional EP2 receptor mediating smooth muscle
relaxation.
The guinea-pig longitudinal muscle is at present widely accepted to be
an EPi selective preparation, however, in view of the above results there
is a need for further study of the nature of the EP receptors present. In
this thesis the EP receptors on both the smooth muscle and neuronal
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elements have been characterised using a range of PGE analogues and
the EPi receptor antagonist, AH 6809.
Analogues investigated (see Figure 4.1 and Table 4.1)
PGE2 analogues (Figure 4.1A)
16,16-dimethyl PGE2'. This prostanoid has been shown to contract the
rabbit aortic strip and induce irreversible aggregation of human
platelets: these effects are abolished by thromboxane receptor blockade
(Jones et al, 1979; 1982). It is a potent EPi receptor agonist, being more
active than PGE2 in contraction of the bullock iris sphincter, rat
stomach fundus strip, guinea-pig trachea, fundus and ileum (Dong et
al, 1986; Coleman et al, 1987; Coleman et al, 1988). It is also highly
active at the EP3 receptors of the guinea-pig vas deferens and the rat
isolated gastric mucosa (Reeves and Stables, 1985; Reeves et al, 1988).
However, Dong et al (1986) found it to be less active than PGE2 at EP2
receptors mediating relaxation of the guinea-pig trachea, cat trachea
and dog hind limb blood flow in vivo . A recent report indicated that
16,16-dimethyl PGE2 was 27 times less active than PGE2 in the cat
trachea (Coleman and Sheldrick, 1988).
ICI80205: Similarly to 16,16-dimethyl PGE2, ICI 80205 has thromboxane
mimetic properties (Dong et al 1986). Jones et al (1979) and Dong and
Jones (1982) also found this compound to have a similar profile to that of
16,16-dimethyl PGE2 at EP receptors, although it appears to be more
selective for EPi receptors. Their studies showed it to be highly active at
the contractile receptors of the bullock iris sphincter, the rat stomach
fundus and the guinea-pig trachea, but inactive as a relaxant agent in
the guinea-pig trachea, and only weakly active in the cat trachea and
the dog hind limb. ICI 80205 has not yet been studied on any EP3
systems.
17-phenyl PGE2~co-trinor: No biological data has been reported in the
literature.
Sulprostone: Coleman et al (1987a) have shown sulprostone to be active
at EPi receptors in the guinea-pig ileum and the guinea-pig and dog
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fundus, where it is only 2-4 fold less active than PGE2. It is, however,
highly potent in all tissues containing EP3 receptors: chick ileum
(Coleman et al, 1987b), guinea-pig vas deferens (Coleman et al 1987c)
and rat isolated gastric mucosa (Reeves et al, 1988). Sulprostone
appears to be devoid of any EP2 agonist activity, being inactive or weakly
active on the cat trachea, guinea-pig ileum circular muscle, and dog
saphenous vein (Coleman et al 1987a).
11-deoxy PGE2 1-alcohol: No biological data is available in the literature.
PGEi analogues (Figure 4.IB)
MB28767: Banerjee et al (1981a and b) found that this compound caused
prolonged inhibition of pentagastrin-stimulated gastric acid secretion by
oral dosing in conscious rats, and was 17 times more potent than their
control compound: 16,16-dimethyl PGE2 methyl ester. Although not
reported as such this may have been due to a potent action on EP3
receptors, now known to be present in this system (Reeves et al, 1988).
However, more recently (Baneijee et al,1985) MB28767 has been shown
to have potent contractile action on the rabbit aorta (EC50, 2 pM) and
mesenteric artery (ECso, 200 nM), the EMR vs U 46619 being -2.5 and 1
respectively. It also induced irreversible aggregation of rat and human
platelets in vitro (Banerjee et al, 1985; Halushka et al, 1987). These
actions are indicative of thromboxane agonist activity.
Oxoprostol: No biological data as yet available in the literature, for
chemistry -see Facchini and Jones (1988).
Misoprostol: Misoprostol (Collins et al, 1985) has been shown to be an
effective anti-secretory agent against a number of stimuli and provides
protection of the gastric mucosa of a range of species (Bauer, 1985;
Hanson et al, 1988). These types of activity have since been associated
with EP3 receptors ( see Coleman et al, 1990). In addition, the
compound is highly active on the guinea-pig vas deferens and the rat
isolated gastric mucosa (Reeves et al, 1988) - both known to contain EP3
receptors. Conflicting results have been reported on the activity of
misoprostol on EPi and EP2 receptors. Coleman et al (1988) reported
results showing a high potency for this compound at EP2 receptors of
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the cat trachea, but low activity in the guinea-pig fundus (EPi). While
Eglen and Whiting (1988) found misoprostol to be equi-active with PGE2
in two EPi contractile preparations (guinea-pig ileum, and oesophageal
muscularis muscle) and 20 times less active in another (guinea-pig
trachea), but inactive as an EP2 agonist (relaxation in guinea-pig
trachea).
11-deoxy PGEp. Dong et al (1986) reported a low activity of this compound
at EPi contractile receptors in the bullock iris sphincter, rat stomach
fundus and the guinea-pig trachea. However, it was found to have
greater activity at EP2 receptors in the guinea-pig trachea, the cat
trachea and the dog hind limb. 11-Deoxy PGEi has not to date been
investigated in any preparations containing EP3 receptors.
Butaprost: Gardiner (1986) has shown that on preparations containing
both EPi and EP2 receptors (guinea-pig trachea and lung, cat lung strip
and human bronchial tissue) the compound acted as a potent relaxant,
in comparison to PGE2 which displayed considerable contractile effects.
In the cat trachea, butaprost was found to be 26 times less potent than
PGE2. However, butaprost was shown to be devoid of activity on the
chick ileum and was only weakly active in the guinea-pig ileum , the





Results are shown in Figure 4.2. All the PGE analogues tested
contracted the chick ileum. At the EC25 level the rank order of potency
was: 16,16-dimethyl PGE2 > ICI80205 > PGE2 > MB 28767 > sulprostone >
butaprost > misoprostol > oxoprostol > 17-phenyl PGE2-co-trinor >11-
deoxy PGE2 1-alcohol.
The log concentration-response curve of PGE2 reached -80% of the Ach
maximum. However, the maxima of some of the analogues tested were
significantly lower: sulprostone (40% ± 4), butaprost (47% ± 3), MB 28767
(56% ± 4) and oxoprostol (-56 %).
Action ofAH 6809
2 pM AH 6809 caused a rightward shift in the log concentration-
response curve of PGE2 (Fig. 4.3). The dose-ratio of 2.7 ± 0.8 was
significant at the P < 0.05. This is consistent with a pA2 of 5.9 for AH
6809.
Interaction of PGE2 and sulprostone
When doses of PGE2 were added to a preparation which had been
precontracted with a supramaximal (220 nM) concentration of
sulprostone, the response levels corresponded closely to those predicted
for an additive interaction between the two agonists (see Fig 4.4 and Fig.
4.5).
The effect of the 'cocktail' of antagonists on PGE2 and Butaprost
The cocktail of antagonists (see discussion) used by Gardiner (1986) had
no effect on the log concentration-resposne curves of PGE2 and butaprost
(Fig. 4.18)
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Figure 4.2: Log concentration-response curves of (a) PGE2
analogues and (b) PGEi analogues for contraction of the chick
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Figure 4.3: Effect of AH 6809 (2gM) on the log concentration-
response curve of PGE2 in the chick ileum (mean of 4 expts.).
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Figure 4.4: (a) Log concentration-response curve of PGE2 in the
absence and the presence of 220nM sulprostone and (b) Log
concentration-response curve of PGE2 alone and that predicted
in the presence of 220nM sulprostone if the inter action of the








































Figure 4.5: Trace showing the contraction of the chick ileum
by cumulative additions of PGE2 and the effect of sulprostone









Relaxation of histamine-induced contractions
The log concentration-response curve of PGE2 was unaffected by the
presence of 10 pM GR 32191, the IC50 being 0.69 ± 0.15 and 0.61 ± 0.11 in
its absence and presence respectively.
In the presence of 10 |iM GR 32191 the rank order of potency of PGE
analogues was as follows: PGE2 > 16,16-dimethyl PGE2 ^ (nat) 11-deoxy
PGE2, (rac) 11-deoxy PGEi > 11-deoxy PGE2 1-alcohol > misoprostol >
ICI80205 > 17-phenyl PGE2-co-trinor > butaprost > MB 28767 >
sulprostone > oxoprostol (see Fig 4.9). For PGI analogues: cicaprost >
iloprost > carbacyclin (Fig. 4.6).
The log concentration-response curves of sulprostone (Fig. 4.9B) and
oxoprostol failed to reach the IC25 level, the maxima being 22 ± 8 (at the
highest concentration tested, 3.6 |iM) and 14 ± 5 % (at the highest
concentration tested, 1.4 pM) respectively. The curve for MB 28767
appears to be bell-shaped, reaching a maximum relaxation of 47 ± 9 %
at 100-400 nM, with an IC25 of 76 ± 40 nM. Concentrations of MB 28767
in excess of 400 nM produced a contractile response (Fig 4.9B).
The effect of the TP-receptor antagonist GR 32191
The TP-receptor agonist, U 46619 produced dose-related contractions of
the preparation, with an EC50 of 4.6 ± 1 nM. In the presence of 10 pM
GR 32191 the log concentration-response curve for U 46619 was subject to
a parallel rightward shift consistent with a pA2 of 7.2 ±0.1 (Fig. 4.7 and
Fig. 4.9C).
In the absence of GR 32191, MB 28767 contracted the vessel rings (EC50,
26 ± 3 nM). At 10 pM the blocker caused a large rightward shift in the
curve. The pA2 could not be accurately measured as the maximum
response obtained in the presence of GR 32191 was 28 ± 15 % at 4.3 pM.
However, an estimate of 7.5 for the pA2 was made from the dose ratio
obtained at the IC25 level.
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The effect ofAH 6809
At a concentration of 2 |iM AH 6809 had no significant (P< 0.001) effect
on the log concentration-response curve of PGE2 (Fig. 4.8), the dose ratio
was 0.87 ± 0.03.
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Figure 4.6: Log concentration-response curves of (a) PGE2
analogues and (b) PGEi analogues for relaxation of histamine-
induced contraction in the rabbit jugular vein (mean of 4-6 expts.).
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Figure 4.7: Effect of GR 32191 (10|iM) on the log concentration-
response curves of U 46619 and MB 28767 for contraction of
the rabbit jugular vein (mean of 4 expts.).
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Figure 4.8: Effect of AH 6809 (2|iM) on the log concentration-
response curve of PGE2 in the rabbit jugular vein (mean of 5 expts.).
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Figure 4.9A: Trace showing the relaxation of the rabbit jugular
vein, precontracted with histamine (l|iM), by (a) PGE2
(b) 11-deoxy PGEj and (c) butaprost. The tissues were bathed


















Figure 4.9B: Trace showing the relaxation of the rabbit jugular
vein precontracted with histamine (l(iM) by (a) sulprostone and
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Figure 4.9C: Trace showing the contraction of the rabbit jugular


















PGE analogues: Log concentration-response curves are shown in
Figure 4.10. All the PGE analogues tested were found to have some
activity as contractile agents. The rank order of potency was as follows:
ICI80205 > 16,16-dimethyl PGE2 > PGE2 > MB 28767 > 17-phenyl PGE2-C0-
trinor > misoprostol > sulprostone > 11-deoxy PGE2 1-alcohol >
oxoprostol > 11-deoxy PGEi > butaprost. The curves for a number of
compounds reached a significantly lower maximum than PGE2: 11-
deoxy PGE2 1-alcohol, 11-deoxy PGEi, oxoprostol and butaprost.
Other prostanoids: The thromboxane mimetic, U 46619 was inactive at
Concentrations up to 3 jiM. PGF2tt contracted the preparation (EC25,
-200 nM), however, the prostanoid retained little activity in the presence
of 2 pM AH 6809. The PGF2a mimetic, ICI 81008 was inactive as a
contractile agent at concentrations up to 2 pM (Table 4.2).
Effect of morphine and TTX
Single dose of PGE2: At a concentration of 1 pM morphine caused a
significant inhibition (38% ± 6) of the response to a single sub-maximal
dose (14nM) of PGE2 . The inhibitory action of 1 pM TTX was similar
(37% ± 3) (Fig. 4.11). Inhibition of a single dose of PGE2 by 100 nM TTX
is shown in Figure 4.17A.
Log concentration-response curves: Log concentration-response curves
are shown in Figure 4.12. At the EC25 level the log concentration-
response curves of sulprostone and 17-phenyl PGE2-co-trinor were
unaffected by the presence of 1 pM morphine and the small shifts in the
curves of ICI80205, 16,16-dimethyl PGE2 and oxoprostol were not
significant. However, the Concentration-response curves of PGE2 and
MB 28767 were subject to a small, but statistically significant, rightward
shift in the presence of morphine.
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Table 4.2: PD25 values of U 46619, PGF2tt, ICI81008 and substance P
in the guinea-pig ileum.
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Figure 4.11: Histograms showing the effect of (a) TTX (lfiM) and
morphine (1|J.M) and (b) AH 6809 (l|iM) on the reponse to a single
submaximal dose of PGE2 (14nM), cicaprost (13nM), iloprost (14nM)




















Figure 4.12: Effect of morphine (M^ (l|iM) on the log concentration-
response curves of (a) PGE2 and (b) PGEX analogues in the
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Misoprostol, 11-deoxy PGE2 1-alcohol, 11-deoxy PGEi and butaprost were
subject to a large highly significant rightward shift in the presence of 1
pM morphine.
Effect ofatropine and SP150
At 200 nM atropine partially inhibited (27% ± 1) responses to a single
submaximal dose (14 nM) of PGE2 (Fig. 4.14).
The log concentration-response curve of PGE2 and 16,16-dimethyl PGE2
were also significantly shifted by 200 nM atropine, while that of
sulprostone was unaffected (Fig 4.13).
The SP blocker, SP150 caused a significant inhibition (22% ± 5) of the
response to 14 nM PGE2 (Fig. 4.17B). However, in the presence of 1 pM
morphine SP150 has no effect on the response to this dose of PGE2 (Fig.
4.14 and 4.17B). In the presence of both SP150 and atropine the response
to PGE2 was inhibited by 47% ± 5. (Fig. 4.17C).
Effect ofAH 6809
In the absence of morphine, 1 pM AH 6809 caused a 67% inhibition of
the response to a single sub-maximal dose of PGE2 (14 nM) (Fig. 4.11).
The effect of AH 6809 on log concentration-response curves is shown in
Figure 4.15. With morphine present, 2 (iM AH 6809 caused a parallel
rightward shift in the log concentration-response curve of PGE2 (dose
ratio, 31), consistent with a pA2 of 7.08 ± 0.14 ( range = 6.3 - 7.4). The
blocker caused a similar degree of shift in the curves of 16,16-dimethyl
PGE2, ICI80205, 17-phenyl PGE2-co-trinor and misoprostol, while that of
oxoprostol was subject to a small but significant shift.
At the 10-30% response level the curve of sulprostone was unaffected by 2
pM AH 6809 but at concentrations giving responses of 40-70% the shift
was similar to that produced in the PGE2 curve. In contrast, at all the
concentrations tested the responses to MB 28767 were unaffected by AH
6809.
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Figure 4.13: Effect of Atropine (200nM) on the log concentration-
response curves of (a) PGE2 (b) 16,16 dimethyl PGE2 and
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Figure 4.15: Effect of AH 6809 (2|iM) on the log concentration-
response curves of (a) PGE2 analogues and (b) PGEi analogues
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Figure 4.16: Effect of AH 6809 (IOjiM) on the concentration-
response curves of (a) PGE2 and MB 28767 and (b) sulprostone








































Increasing the concentration of AH 6809 to 10 p.M (Fig. 4.16) caused a
greater shift in the curves of PGE2 (dose ratio, 52), however, the curve of
MB 28767 was not shifted.
Inhibition of Histamine-induced contractions
There was no evidence of inhibition of histamine responses with PGE2
however, in some preparations potentiation of the histamine
contractions could be observed at doses which produced no observable
increase in the resting tone of the preparation (see Figure 4.17D).
Butaprost had no effect on the contractions at any of the concentrations
tested in 2/4 preparations (Figure 4.17D) but slightly potentiated the
actions of histamine in the other two preparations.
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Figure 4.17A: Trace showing the effect of (a) TTX (lOOnM)
and (b) AH 6809 (lpM) on the contractile action of PGE2 (14nM)
in the guinea-pig ileum.
137
 
Figure 4.17B: Trace showing the effect of (a) SP 150 (l|iM)
and (b) SP 150 (lfiM) in the presence of morphine (ljiM)


















Figure 4.17C: Trace showing the effect of atropine (200nM)





Figure 4.17D: Trace showing the effect of (a) butaprost and
(b) PGE2 on contractions of the guinea-pig ileum induced
by histamine. The tissues were bathed in Tyrodes solution







The results obtained in the chick ileum (Table 4.3) appear to confirm
that the tissue contains an EP3 receptor: (1) contractions are only subject
to a small shift (Dose ratio = 2.7) in the presence of AH 6809 and (2) those
compounds which are highly active as inhibitors of the twitch response
in the guinea-pig vas deferens (Jones, unpublished: Table 4.4A) are also
active as contractile agents in this tissue (16,16-dimethyl PGE2, ICI
80205, sulprostone, MB 28767 and misoprostol). However, there are a
number of anomalies in the results obtained. Firstly, in the chick ileum
a number of these PGE analogues have a considerably lower maximum
than PGE2: they are sulprostone, MB 28767 and oxoprostol. It is possible
that these compounds are partial agonists at the EP3 receptor, or that
they have contractile and relaxant actions which effectively cancel one
another out. However, the PGE2 concentration-response curve in the
presence of a supramaximal concentration (220 nM) of sulprostone fits
that predicted for an additive interaction of the two compounds.
Secondly, the PGEi analogue butaprost, which is inactive as an
inhibitor of the twitch response in the guinea-pig vas deferens (Table
4.4A), is highly active as a contractile agent in this preparation.
However, the maximum response of 47% at -100 nM is again lower than
that obtained for PGE2. These results are at variance with those of
Gardiner (1986) who found butaprost to be inactive in the chick ileum
over a wide concentration range (2 nM - 200 pM). The experiments were
carried out in Krebs solution containing a mixture of receptor
antagonists (hyoscine 0.1 (ig/ml, mepyramine 0.1 fig/ml,
phenoxybenzamine 0.1 (ig/ml, propranolol 3 |ig/ml and methysergide
0.2 pg/ml) and indomethacin (3 |iM). However, as shown in Figure 4.18
the presence of this cocktail had no effect on the activity of butaprost.
Butaprost has been shown (Gardiner, 1986) to be active in preparations
containing EP2 receptors (relaxation of the cat/guinea-pig trachea), but
to have low EPi activity (contraction of the guinea-pig trachea, guinea-
pig ileum). We have confirmed these results in the guinea-pig trachea
(Jones, unpublished: Table 4.4B) and ileum. Thus, it may be postulated
that the chick ileum contains an EP2 receptor mediating contraction in
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TABLE 4.3: PD25 values and equi-effective molar ratios (EMR) of
prostanoids in the chick ileum (mean of 4-6 expts.). (± s.e.m)
PROSTANOID pD25 EMR
PGE analogues
pge2 8.39 ± 0.06 1
16,16 dimethyl PGE2 8.58 ± 0.06 0.32 ± 0.03
ICI80205 8.62 ± 0.45 0.44 ± 0.15
17-phenyl PGE2 7.40 ± 0.13 13 ± 2
sulprostone 8.18 ± 0.41 1.9 ± 0.45
MB28767 8.52 ± 0.12 1.3 ± 0.1
oxoprostol 7.26 ± 0.16 12 ± 5
misoprostol 7.69 ± 0.21 4.9 ± 2.1
11-deoxy PGE2 1-alcohol 6.68 -L 0.06 65 _L 20rr




TABLE 4.4A: pDso values and equi-effective molar ratios (EMR) of PGE
analogues for the inhibition of twitch of the guinea-pig vas deferens
and contraction of the guinea-pig trachea (mean of 4 expts. except
oxoprostol, 11-deoxy PGE2 1-alcohol and butaprost, 3 expts).
Jones, unpublished.
PROSTANOID Guinea-pig vas deferens Guinea-pig trachea
PD50 EMR Pd50
pge2 8.76 ± 0.03 (1)
16,16 dimethyl PGE2 9.62 ± 0.08 (0.13) 9.72 ± 0.06
ICI80205 9.02 + 0.10 (0.76)
17-phenyl PGE2 7.96 ± 0.06 (6.3) 8.68 ±0.10
sulprostone 9.69 ± 0.03 (0.15) 8.14 ± 0.07
MB28767 8.97 ± 0.10 (0.72)
oxoprostol 8.38 (3.1)
misoprostol 9.12 ±0.07 (0.51)
ll-deoxyPGE2 1-alcohol 7.81 (10.5)
butaprost < 6.0 (>900)
Table 4.4B: Equi-effective molar ratios of PGE analogues for the
relaxation of the guinea-pig trachea and cat trachea (3-4 expts).
Equi-effective Molar Ratio
Prostanoid Guinea-pig trachea Cat trachea
pge2 1.0 1.0
ll-deoxyPGE2 1-alcohol 9.5 -
11-deoxy PGEi 11 * 13 *
Misoprostol 1.0 3 7 **
Butaprost 3.8 27 ***
* Dong et al, 1986; ** Coleman et al, 1988; *** Gardiner, 1986.
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Figure 4.18: Effect of a cocktail of antagonists (see Gardiner, 1986)
on the log concentration-response curves of (a) PGE2 and




















addition to the EP3 receptor. The existence of a second receptor in the
tissue would also explain the low maximum of the EP3-selective
compounds: sulprostone, MB 28767 and oxoprostol. However, as will be
discussed in the following section, the results obtained show butaprost
to be considerably less active than PGE2 (EMR -700) at the EP2-receptors
in the rabbit jugular vein. In addition, the profile of action of 11-deoxy
PGE2 1-alcohol is the reverse of that of butaprost: it is only 4 fold less
active than PGE2 as a vasorelaxant in the rabbit jugular vein, but 65
times less active in contracting the chick ileum. On the basis of these
results it is could be postulated that the EP2 receptors present in the two
tissues are different.
A number of problems must be addressed in relation to this hypothesis
(1) why do the EP1/EP3 selective agonists, ICI 80205 and 17-phenyl PGE2
reach a maximum response ? (2) why is there a significant shift in the
log concentration-response curve of PGE2 in the presence of the EPi
receptor antagonist, AH 6809 ? One could postulate that the EP2 receptor
in the chick ileum is considerably more sensitive to ICI 80205 and 17-
phenyl PGE2 than that found in the RJV, however this seems unlikely
as there is no evidence of relaxation of the guinea-pig trachea (Table
4.4A) or the cat trachea (Dong et al, 1986) with these agonists. It could
however, be postulated that the chick ileum contains, in addition to the
EP3 receptor, a new EP receptor subtype. These hypotheses will remain
purely conjecture until selective antagonists for these subtypes become
available.
Rabbit jugular vein
The data obtained (Table 4.5) would suggest that relaxation of the rabbit
jugular vein (RJV) by PGE analogues is mediated by an EP2 receptor.
Firstly, the responses are unaffected by the EPi-receptor blocker,
AH6809 at a concentration which produces a large shift in the
concentration-response curve to PGE2 in preparations containing EPi
receptors (see guinea-pig ileum). In addition, the EP1/EP3 selective
agonist, sulprostone is virtually inactive as a vasorelaxant in this
preparation; earlier work has shown the compound to have little EP2
activity (Coleman et al, 1987a). Finally, a number of compounds which
displayed solely relaxant actions in the guinea-pig trachea (11-deoxy
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TABLE 4.5: pDso and equi-effective molar ratio (EMR) of
prostanoids in the rabbit jugular vein (mean of 4-6 expts.).
PROSTANOID pD50 EMR
PGE analogues
pge2 9.34 ± 0.11 1
16,16 dimethyl pge2 9.21 ± 0.19 2.1 ± 0.5
ICI80205 7.25 ± 0.17 83 ± 15






misoprostol 8.21 ± 0.21 8.3 ± 1.7
11-deoxy pge2 1-alcohol 8.27 ± 0.16 4.6 ± 0.59
(nat) 11-deoxy pgei 9.35 ± 0.12 1.4 ± 0.59
(±) 11 -deoxy PGE 1 9.22 ± 0.14 2.05 ± 0.64
butaprost 6.70 ± 0.10 685 ± 194
PGI analogues
cicaprost 8.02 ± 0.19 —
iloprost 7.90 ± 0.08 —
carbacyclin 7.26 ± 0.19
* calculated using the ic25 values.
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PGE2 1-alcohol, 11-deoxy PGEi and misoprostol) are highly active in the
RJV.
The preparation is highly sensitive to PGE2 (IC50, 0.61 nM), considerably
more so than the cat trachea (IC30, 40 nM: Dong et al, 1986; IC50, 20 nM:
Coleman et al, 1988a) or the guinea-pig trachea (IC30, 10 nM: Dong et al,
1986). Thus, this preparation may prove very useful in study of the EP2
activity of PGE analogues. The usefulness of the RJV is demonstrated
in assessment of the potency of 17-phenyl PGE2-co-trinor (EMR, 200). An
accurate estimate of the EP2 activity of this compound would not have
been possible from the cat trachea (due to the insensitivity of the
preparation) or the guinea-pig trachea (due to the high potency of the
compound on the EPi receptors mediating contraction).
The results obtained confirm those of Dong et al (1986) showing that
16,16-dimethyl PGE2 has considerable activity at EP2 receptors
mediating relaxation of the cat trachea. ICI 80205 has less EP2 activity
in the rabbit jugular vein, again consistent with the results obtained by
Dong et al (1986) on the relaxation of the guinea-pig/cat trachea.
The data is at variance with that of Eglen and Whiting (1988) who found
that at 300 nM misoprostol elicited contractions of the guinea-pig
trachea, with no evidence of relaxation. However, Coleman et al (1988a)
found misoprostol to be highly active at EP2 receptors mediating
relaxation of the cat trachea. In addition, it has recently been shown
(Jones et al, 1989) that at 200 nM'the compound rapidly abolishes
submaximal contractions of the guinea-pig trachea induced by
persistent TP receptor agonists such as EP 171. A possible explanation
for this discrepancy may be that Eglen and Whiting used zig-zag
preparations while we have used rings, although this is unlikely to
account for such a large difference.
11-Deoxy PGEi and 11-deoxy PGE2 1-alcohol appear to be active EP2
agonists. They also appear to be more selective for this subtype than
misoprostol having less EPi (guinea-pig trachea/ileum) and EP3 activity
(guinea-pig vas deferens), and may prove useful in the investigation of
EP2 receptors.
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As mentioned earlier, work by Gardiner (1986) suggested that butaprost
is a highly selective EP2 agonist. Studies by Jones (unpublished) have
also shown that the compound is active as a relaxant in the guinea-pig
trachea with no evidence of contractile activity. However, in the RJV
butaprost appears to be considerably less active at EP2 receptors than
predicted from the above results. As will be discussed later, this
preparation is known to contain TP-receptors mediating contraction,
however the experiments were carried out in the presence of 10 pM GR
32191, a potent TP-receptor blocker. In addition, Gardiner (1986) found
the compound to be inactive in the guinea-pig lung and the guinea-pig
trachea - both known to contain TP receptors.
It may be that the potency of PGE2 as a relaxant in the guinea-pig
trachea is being vastly underestimated, thus making EP2-selective
agonists appear considerably more active relative to PGE2 in this
preparation. However, this would not explain the finding that in the
guinea-pig trachea 11-deoxy PGE2 1-alcohol is less active relative to
PGE2 than butaprost, while in the RJV it is considerably more active.
Another possible explanation may be the presence of esterase activity in
one of these tissues which produces the free acid form of butaprost from
its methyl ester, the former having greater activity at EP2 receptors.
However, preliminary experiments (Jones, unpublished) show that the
anticholinesterase, diisopropyl-fluorophosphonate (DFP) had no effect
on the concentration-response curve of butaprost in the guinea-pig
trachea. In addition, one would expect such enzyme activity to
similarly affect misoprostol (see figure 4.1), however, this compound
has the same order of activity in both preparations.
It may be that the RJV contains a subtype of the EP2 receptor distinct
from that found in the guinea-pig trachea, cat trachea and chick ileum.
However, this hypothesis cannot be confirmed without highly selective
EP2 agonists and antagonists - which are not, as yet, available.
We have confirmed data obtained by Giles et al (1989) showing that the
tissue contains a TP receptor, which is highly sensitive to U 46619 (EC50,
4.6 nM). The contractile action of MB 28767 would appear to be mediated
by an action on the thromboxane receptor as its actions are inhibited by
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the TP receptor blocker GR 32191. The relative potency of the compound
us U 46619 (6.5 ± 0.7) is slightly higher than that obtained at
thromboxane receptors of a range of tissues (Banerjee et al, 1986;
Halushka et al, 1987).
It is notable that the pA2 (7.2) of GR 32191 against U 46619 is
significantly lower than that reported for other tissues (Lumley et al,
1987) - this finding is discussed in detail in Chapter 5. However, the
shift of -200 in the concentration-response curve produced by 10 (iM GR
32191 is sufficient to give an indication of the EP2 activity of MB 28767
and to eliminate the TP agonist action of ICI 80205 at the doses
producing relaxation. In the presence of the blocker the concentration-
response curve for relaxation of histamine-induced contractions of MB
28767 is bell-shaped, indicating that the EP2 relaxant activity is being
overcome by the TP contractile action at high doses.
In conclusion, the rabbit jugular vein appears to contain a highly
sensitive EP2 receptor system mediating relaxation. In the presence of
thromboxane receptor antagonists the preparation is most useful in the
study of the EP2 selectivity of a range of PGE analogues. However, the
nature of the EP2 receptor in relation to those present in other
preparations (guinea-pig trachea and cat trachea) requires further
study.
Guinea-pig ileum
As previously reported (Sanner,1971; Kadlec et al, 1971) we have found
that the contractile response of the guinea-pig ileum to PGE2 has a
component due to the action of activation of enteric neurones (Table 4.6),
which is inhibited to a similar extent by both TTX and morphine.
Studies with atropine and the substance P antagonist, SP 150 indicate
that both acetylcholine and substance P are released. As was found for
the IP system (see Chapter 3) the effects of the blockers is additive, and
neither has any further activity in the presence of 1 |iM morphine.
The concentration-response curves for misoprostol, 11-deoxy PGE2 1-
alcohol, 11-deoxy PGEi and butaprost are subject to a large shift in the
presence of 1 pM morphine (Table 4.7). As discussed above these
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Table4.6:hPD25valu sforPGEanaloguesit bs ncendpresofMo phin(l M)ndAH6809(2 ). PROSTANOIDMAX.pD25p 25 (%ACH)MORPHINEAH6809 (l|iM)2(lM) pge288±38.96±0.178.42±0.176.88±0.13 16,16dimethylPGE290±29.38±0.119.19±0.117.66±0.10 ICI8020596±19.54±0.279.28±0.247.95±0.11 17-phenylPGE296±18.10±0.108.11±0.107.31±0.12 sulprostone75±47.92±0.077.86±0.067.39±0 23 MB2876767±48.50±0.117.85±0.197.58±0 20 oxoprostol45±37.03±0.166.34±0.285.69±0 14 misoprostol70±78.10±0.096.55±0.09>5.89 11-deoxyPGE2 1-alcohol35±7.11±0.14<5.52 11-deoxyPGEi45±66.87±0.22<5.70 butaprost36±56.67±0.28<5.92
Table 4.7 : The effect of Morphine (lpM) and Atropine (200nM)
on the dose-response curves of PGE2 analogues in the guinea-




pge2 3.58 ± 0.38 * 4.66 ± 2 *
16,16 dimethyl pge2 1.62 ± 0.24 2.40 ± 0.24*
ICI80205 1.96 ± 0.19
—
17 phenyl pge2 0.94 ± 0.04 —
sulprostone 1.15 ± 0.03 1.40 ± 0.27
MB28767 5.2 ± 1.4*
—
oxoprostol 4.0 ± 1.2
misoprostol 42 ***
11-deoxy pge2 1-alcohol >50 —
11-deoxy pgei >20 —
butaprost >10
*** P < 0.001
** P < 0.01
* P < 0.05
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compounds have been shown to be active at the EP2 receptors in a range
of tissues: rabbit jugular vein, guinea-pig trachea (Jones, unpublished
Table 4.4), cat trachea (Dong et al, 1986; Coleman et al, 1988; Gardiner,
1986). In contrast, those compounds whose activity was not
significantly affected by morphine (ICI 80205, sulprostone, 17-phenyl
PGE2-co-trinor and oxoprostol) have low activity at the EP2 receptors of
the RJV, and are contractile agents in the guinea-pig trachea. On the
basis of these results one could suggest the receptor subtype mediating
the indirect action of PGE analogues in the guinea-pig ileum is EP2.
Poll et al (1988a) showed that in the presence of 10 pM AH 6809 (see
introduction), PGE2 caused a concentration-related potentiation of
electrically-induced contractions, and reversed inhibition produced by
indomethacin (1-30 pM). The authors suggest that excitatory neuronal
responses to PGE2 in the guinea-pig ileum are mediated by a receptor
other than EPi. However, although their data suggests the existence of
a receptor additional to EPi, a neuronal site of action cannot be definitely
concluded from these experiments (see Hedqvist, 1980). Recently,
however, the group (Poll et al, 1988b) have demonstrated that this
potentiating action of PGE2 is inhibited by cyclopentyladenosine, known
J MuSft.cU(0
to act presynaptically to inhibit transmitter release (Gintzler^ 1975;
Fredholm & Dunwiddie, 1988.).
Classification of the neuronal EP receptor, at this stage, must be purely
tentative for a number of reasons. Firstly, studies lack a compound
which is a potent and selective EP2 "receptor agonist / antagonist. In
addition, the situation is made more complex by the conflicting results
obtained in studies of the EP2 receptors of the rabbit jugular vein, cat
trachea and guinea-pig trachea which raise the possibility of the
existence of subtypes of the receptor.
Some of the results presented on the action of butaprost in this
preparation are at variance with those of Gardiner (1986). Firstly,
Gardiner (1986) found that the concentration-response curve for this
compound was bell-shaped - the maximum response being <20% of the
tissue maximum at l|iM. In contrast, the results presented in this
thesis show that the concentration-response curve of butaprost has no
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evidence of belling and 36% of the tissue maximum is reached at the
highest concentration tested, 3gM. Secondly, Gardiner (1986) reported
an inhibitory action of the compound on histamine-induced contractions
at concentrations of 3 and 10|iM. However, as is shown in Figure 4.17
no such inhibition was evident in the results obtained.
The experiments of Gardiner (1986) involve concentrations of butaprost
of up to 200pM, which would require aqueous stock solutions of
~2mg/ml. However, in our hands when a 2mg/ml solution of the
compound, in 100% ethanol, was diluted to 100pg/ml in saline
opalescence appeared. The solution did not clear on warming. It
should be noted that butaprost is a methyl ester thus the addition of
sodium bicarbonate does not increase its aqueous solubility as with free
acid prostanoids. Thus the aqueous top stock used in the experiments
presented here was 50|ig/ml - a dilution into saline of a lmg/ml ethanol
solution. It may be that Gardiner (1986) has used a high proportion of
ethanol/DMSO to ensure solubility of high concentrations of butaprost
and these agents are responsible for the inhibitory effects observed.
Our studies have shown that the EPi blocker, AH 6809, causes a parallel
rightward shift in the concentration-response curve of PGE2, consistent
with a pA2 of 7.08 ± 0.14 (6.3-7.4). AH 6809 also produced a large shift in
the concentration-response curves of 16,16-dimethyl PGE2, ICI 80205
and 17-phenyl PGE2-co-trinor (Table 4.8), this is not unexpected as these
compounds are all highly active at EPi receptor sites in the guinea-pig
trachea (Table 4.4). However, certain results indicate the presence of
another contractile receptor in addition to EPi: both sulprostone (at
concentrations giving 10-30% responses) and MB 28767 are resistant to
block by 2(iM AH 6809. Similar results were obtained using 10 (iM AH
6809.
It is unlikely that this effect is due to an action of the compounds on TP
receptors as the TP-receptor agonist, U 46619 is inactive in this
preparation. In addition, the contractile action of PGF2a is blocked by
AH 6809 indicating that it is acting at EPi receptors. Both sulprostone
and MB 28767 are highly active in the chick ileum and the guinea-pig
vas deferens, indicating that the AH 6809-resistant receptor of the
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Table 4.8: Effect of AH 6809, 2 |iM ( mean of 4-6 expts) and IOjiM
(2 expts) on the concentration-response curves on PGE and PGI
analogues in the guinea-pig ileum.
PROSTANOID DOSE RATIO IN THE PRESENCE OF AH6809
2jiM 10|iM
PGE analogues
pge2 31.2 ± y *** 52.5
16,16 dimethyl pge2 24.2 ± 5 ***
ICI80205 12.6 + I ***
_
17-phenyl pge2 11.5 ± 2 ***
sulprostone 3.5 ± 2 4.6
MB28767 1.8 ± 0.5 1.6
oxoprostol 3.9 ± 1 *
misoprostol >10 :*
PGI analogues
iloprost 245 ± 57 ***








guinea-pig ileum may be EP3. The shift in the sulprostone curve at
higher concentrations reflects its activity at EPi receptors, also seen in
the guinea-pig trachea (Table 4.4a).
In conclusion, the data presented demonstrates that the guinea-pig
longitudinal muscle contains EP receptors additional to the EPi subtype
(see Fig 4.19). Thus, data claiming EPi selectivity of a compound on the
basis of high activity in this preparation should be interpreted with
caution. In order to state unequivocally the receptor subtype involved
one should investigate the effect of both morphine and AH 6809 on the
contractile action. Making use of these blockers, however, the guinea-
pig ileum remains a useful tissue in assessing the EP selectivity of PGE
analogues. It is notable that other tissues used to measure EPi activity
(see introduction) have added complications: the guinea-pig trachea has
highly sensitive EP2 receptors mediating relaxation and recent work by
Jones (unpublished) suggests that the guinea-pig fundus may have an
additional population of EP receptors which are resistant to block by AH
6809 (possibly EP3).
Structure-Activity Relationships
Previous work has shown that certain structural features are essential
for EP receptor agonists activity. These are as follows:
(a) An a chain of 7 carbon atoms (Grudzinskas et al, 1980).
(b) A cyclopentane ring (Grudzinskas et al ,1980).
(c) A substituent at C9, usually carbonyl (Lin et al, 1976; Kimball et al,
1979; Carpio et al, 1987).
(d) A hydroxyl group at C15 or C16 (Grundzinskas et al, 1980; Floyd et
al, 1980).
All the analogues fulfil these criteria, however there is considerable
variation in the activity of these compounds at the various EP receptor
subtypes studied.
The results confirm earlier findings (Grundzinskas et al, 1980; Hess et
al, 1980; Schaaf et al, 1981) that the substitution of a
methanesulphonamido group at CI (sulprostone) greatly reduces EP2
activity, leaving EPi and EP3 unaffected. Loss of the 11-hydroxy group
(11-deoxy PGE2 1- alcohol, 11-deoxy PGEi, MB 28767 and oxoprostol)
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reduces the EPi activity of these analogues but is not essential for
EP2/EP3 activity (see Grudzinskas et al 1980; Carpio et al, 1987; Floyd et
al, 1987). The 16-methyl group (16,16-dimethyl PGE2) appears to
enhance both EPi and EP3 activity, with only small loss of EP2 activity.
The results are consistent with those of Banerjee et al (1981a) showing
that the presence of the 16-phenoxy group (ICI 80205, sulprostone, MB
28767 and oxoprostol) leads to potent EP3 activity but reduces EP2
actions. The addition of a halogen (ICI 80205) appears to enhance the
potency at EPi and EP3 receptors. Finally, substitution of the terminal
n-propyl unit by phenyl leads to EPi selectivity, reduced activity at EP3
receptors and little EP2 receptor activity.
In summary, the results indicate that a number of the compounds
studied may prove useful in the classification of EP receptors (see Fig
4.20):
EPj: 17-phenyl PGE2-co-trinor appears to be the most selective EPi
agonist tested: it is highly active in the guinea-pig trachea and ileum
and is 200 times less active than PGE2 in the rabbit jugular vein.
However, the compound retains a certain degree of EP3 activity.
EP2: As previously demonstrated (Gardiner, 1986) the results show the
butaprost has no activity at EPi or EP3 receptors, thus it is useful in the
study of EP2 receptors. However, in certain EP2 systems (rabbit jugular
vein) it is 700 times less active than PGE2. 11-deoxy PGE2 1-alcohol and
11-deoxy PGEi are potent EP2 agonists, however, they lack the selectivity
of butaprost.
EP3: The data confirms that sulprostone is devoid of activity in the most
sensitive EP2 system as yet characterised (rabbit jugular vein), however,
it retains potent agonist action at EPi receptors. MB 28767 may prove
more useful an EP3 selective agonist than sulprostone: it has low EP2
activity and shows no evidence of EPi agonist action in the guinea-pig
trachea or guinea-pig ileum. However, experiments show that the
analogue has considerable agonist action at TP receptor.
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The first description of thromboxane A2 was based on superfusion
bioassay experiments carried out by Piper and Vane (1969). They
detected the release from the passively sensitized guinea-pig lung, when
challenged with antigen, of a labile material which contracted the rabbit
aorta and affected the other tissues much less than stable
prostaglandins. The substance was called rabbit aorta contracting
substance (RCS). Later, Hamberg et al (1974) identified and named the
major component of RCS as thromboxane A2 (TXA2), a highly unstable
intermediate in the conversion of prostaglandin G2 to thromboxane B2.
TXA2 is highly potent as a stimulator of platelet aggregation (Svensson
et al, 1976; Kinlough-Rathborne et al, 1977; Moncada and Vane, 1978)
and a constrictor of vascular and other types of smooth muscle
(Hamberg et al, 1975; Needleman et al, 1976; Moncada et al, 1976;
Tuveno et al ,1976; Svensson and Fredholm, 1977; Ellis et al, 1977;
Dusting et al 1978). In addition, TXA2 has been implicated in the
pathophysiology of a range of conditions including: thrombosis and
occlusive vascular disease (Fitzgerald et al, 1987; Green and
Vesterqvist, 1986; Catella et al, 1987).
As mentioned above, TXA2 is highly unstable with a half-life of about 30
seconds at 37°C and pH 7.4. By comparison with the time courses of
action of the other natural prostanoids, it would seem unlikely that
TXA2 establishes equilibrium occupancy at TP receptors within its half-
life. This poses a major difficulty in studying the pharmacology of TP
receptors and in particular the properties of TP receptor antagonists. It
has therefore been necessary to develop stable and specific TXA2
mimetics (TP receptor agonists) (Fig. 5.1A). One of the first to be
synthesized was 11,9- epoxymethano PGH2 (U 46619). Although strictly
an analogue of PGH2, it has been shown that this compound has a
profile of activity very similar to that of TXA2 (Fitzpatrick et al, 1978;
Maclntyre et al, 1978) and as yet, it has the most favourable combination
of potency, specificity and rapidity of action (Jones at al, 1989). Jones
and Marr (1977) showed that replacing the terminal 4 carbon unit of
PGF2a with a p-flurophenoxy group produced a compound with a 50 fold
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Figure 5.1A: Structure of TP-receptor agonists
ICI79939 ll-deoxy-16-p-chlorophenoxy
co-tetranor PGF2a
Figure 5. IB: Structure of TP-receptor antagonists
,COOH ,COOH
PTA-OH ONO 11120
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increase in potency at TP receptors in various isolated preparations (ICI
79939 - Dukes et al, 1974). A similar substitution on ring analogues of
PGH2 has led to synthesis of EP 031 and EP 171, both highly potent TXA2
mimetics (Jones et al,1989). Other potent TXA2 mimetics include a thia
derivative of TXA2, lla-carba-9,ll-thia TXA2 (STA2) (Katsura et al,
1983).
A range of structurally diverse compounds have been synthesized
which specifically antagonise the actions of thromboxane mimetics in
both platelet and vasculature of a number of species (Fig 5.IB). The TP
receptor antagonists can be divided into three distinct categories.
Firstly, those which are modified thromboxane / endoperoxide
structures. The original TXA2 antagonists were of this type: LeBreton
et al (1979) demonstrated that 13 azapostanoic acid (APA) inhibited
aggregation to PGH2 and a similar profile was demonstrated for pinane
TXA2 (PTA2) (Nicolaou et al, 1979). However, subsequent studies (Jones
et al, 1984) have shown that PTA2 is, in fact, a partial agonist. Jones et
al (1984) and Wilson and Jones (1985) produced the TP receptor
antagonists EP 045 and the more potent EP 092, which retain the
natural a chain and bicyclo [2.2.1] heptane ring but have a
semicarbazone modification to the co chain. Finally, ONO 11120
(Katsura et al, 1983) is a TXA2 antagonist developed from the
combination of 2 classes of antagonist, the aza prostanoids and the
pinane series. The second category of antagonists include compounds
with prostanoid structures bearing little resemblance to
thromboxane/endoperoxides. AH 23848 (Brittain et al, 1985) and GR
32191 (Lumley et al,1987) nominally have the PGD ring structure with a
modified co chain and addition to the C9 hydroxyl of a 4-phenylbenzyl
group.
The final group of antagonists bear no relation to the prostanoid
structure; this group includes BM 13,177 (Patscheke et al, 1984) which is
a sulphonamide derivative.
Lefer et al (1981) were first to claim a dissociation between the platelet
and vascular actions of thromboxane: they found that carbacyclic TXA2
(CTA2) was a vasoconstrictor in the cat coronary artery but antagonised
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arachidonic acid-induced aggregation of human platelets (platelet rich
plasma, PRP). A number of other early studies (Gorman et al, 1981b;
LeDuc et al, 1981) have also suggested differences between the TP
receptor on the platelet and vasculature. However the results have to be
interpreted with caution for the following reasons. Firstly, many of the
platelet studies employed PRP. Analogues which are lipophylic will
bind to the plasma proteins present in PRP and this will result in a
considerable decrease in the effective free concentration. Secondly,
these groups did not investigate the ability of compounds to induce
platelet shape change, which would indicate partial agonist properties.
In the platelet, partial agonists may cause shape change but not a full
aggregation wave. The shape change and even small aggregation waves
are not always obvious if the test compound is added to the PRP at room
temperature before placing in the heated cell block of the aggregometer.
It is notable that CTA2 has been shown to induce a rapidly reversing
aggregation wave and also inhibits the aggregating wave of U 46619,
indicating partial agonist activity (Armstrong et al, 1986). Finally, the
platelet contains IP and DP receptors which mediate inhibition of
aggregation - agonist activity of thromboxane analogues at these
receptors may reduce their effectiveness as aggregatory agents.
Studies by Mais et al (1985a, 1988) have demonstrated a difference in the
rank order of potency of a range of 13-azapinane TP receptor antagonists
in the platelet and vasculature (saphenous vein) of both the human and
the dog. The problem of plasma protein binding has been eliminated
from these later studies as washed platelets have been used. In
addition, this group (Mais et al, 1985c) have resolved three of the
analogues used in the above study (ONO 11120, PTA-OH and I-PTA-OH),
and found that in the saphenous vein one of the enantiomers, of all
three compounds, was ~3 times more potent than the other, while in the
platelet the epimers were of equal potency. The authors concluded that
there was a difference in the TP receptor present in the platelet and
vasculature.
More recent investigation of a wide range of structurally distinct agonist
and antagonists in both platelet and vasculature (Swayne et al, 1988;
Jones et al, 1989) show no differences in the rank order of potency at the
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two TP receptors involved. Thus, the hypothesis for the existence of
distinct receptors on the platelet and vasculature is based on differences
seen within a close series of 13-azapinane TP receptor antagonists.
A number of groups (Burke et al, 1983; Jones et al, 1987; Narumiya, et al,
1986; Swayne et al,1988) have found the rabbit platelet to be 20 - 300 times
less sensitive to TP-receptor antagonists than those of other species.
Recently, Jones et al (1989) have demonstrated that the pA2 values of a
wide range of structurally distinct TP receptor antagonists are
significantly lower in the rabbit platelet and aorta as compared to
platelet and vessels from other species, however no such difference is
observed with TP receptor agonists.
As yet, studies on the nature of the vascular TP receptor in the rabbit
have been restricted to the aorta. We have extended the study to include
investigation of the action of TP receptor agonists and antagonists in the
jugular vein. One reason for this is the requirement to effectively block
TP receptors in this preparation when studying the EP2 receptor
mediating relaxation (see Chapter 4).
Several attempts have been made to characterise platelet TP receptors
biochemically using radiolabelled analogues. Hung et al (1983) used
[3H]-13-azaprostanoic acid (APA) and found two classes of binding
activity on the human platelet membrane: one with a Kd of -100 nM and
the other with a Kd of -3.5 pM. Halushka et al (1985) used [125I] cis-APA
and described a single class of binding sites, however, the compound
had a high Kd of 1.48 pM. Armstrong et al (1983) investigated the
binding of [3H]-15(S) 9,11- epoxymethano PGH2. They found that the Kd
was approximately 70 nM and binding could be displaced by a wide
range of agonists and antagonists. However, the compound had a large
component of non-displaceable binding. Similar results were obtained
by Kattleman et al (1986) who demonstrated binding of [3H]-11,9-
epoxymethano PGH2 (U 46619) to a single class of binding site on the
human platelet (Kd, 108 nM), which was displaced by a series of TP
receptor antagonists. However, the above assays have been made
difficult by the low affinity and specific activity (<20 Ci/mmol) of the
ligands used.
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Mais et al (1985b) prepared radioiodinated 13-aza-13,14-dihydro-16 (p -
hydroxy-m-iodophenyl)-co-tetranor PTA2 ( [125I]-PTA-OH ) and showed
that the process did not affect the biological activity of the compound
(antagonism of platelet aggregation). They found that [125I]-PTA-OH
bound to a single class of receptor with a of 21 nM and specific
binding of 40-50%. The epimers of the iodinated ligand had equal
activity on human platelets. These results have since been confirmed by
Narumiya et al (1986) and Halushka et al (1987) who also investigated
the displacement of the ligand by a range of analogues and compared
the IC50 values with those obtained for platelet aggregation in vitro. The
results showed that the rank order of potency for agonists correlates
well. Thus, [125I]-PTA-OH appears to be a most useful high affinity,
high specific activity (2000 Ci/mmol) ligand for the study of TP receptors.
More recently, however, the TP receptor antagonist SQ 29, 548 (Ogletree
et al, 1985) has been radiolabeled with tritium and the binding to
human platelets characterised (Hedberg et al, 1988). The compound
was shown to bind to a single class of receptors with a K<j of 5nM and
specific binding was 90-97% of the total binding.
We have used [125I]-PTA-OH to investigate the binding of various TP
receptor agonists and antagonists to the human platelet. The aim of the
study is two fold. Firstly, to further characterise agonist binding at TP
receptors, particularly that of EP 171, the most potent TP receptor
agonist so far reported (Jones et al, 1989). EP 171 is similar in structure
to EP 031 (see Fig.5.1) which has been shown to have a particularly slow
rate of onset and offset. The assumption was made that this was due to
the removal of the highly lipophyllic analogue from the extracellular
space into adjacent lipid domains. However, studies have shown that
EP 171, although considerably less lipophyllic, also has a very slow rate
of onset and offset such that concentration-response curves often cannot
be obtained by cumulative addition of EP 171. Secondly, we were
approached by Glaxo to see if we would be willing to measure the Ki of
two of their potent TP receptor antagonists, AH 23848 and GR 32191 and
the EPi receptor antagonist, AH 6809 on human platelets. The




Non-specific binding: The non specific binding, calculated by including
1 |iM ONO 11120 in the assay mixture, was 50-60% of the total binding.
This value and the of 69 ± 14 for U 46619 correspond to those obtained
in previous studies.
Kd(nM) specific binding Reference
[125i]_ptA-OH U 46619 (% of maximum)
21 ± 5 84 ± 10 60% Mais etal (1986)
22 ± 3 125 ± 17 40% Narumiya et al (1986)
-20 140 ± 13 40-50% Halushka et al (1987)
Agonist displacement curves: The displacement curves are shown in
Figure 5.2. The rank order of affinity of the compounds tested was: EP
171 > EP 031 > 16-p-chlorophenoxy-u/-tetranor-ll-deoxy PGF2a > STA2 >
U 46619 > ICI 79939. The log concentration-inhibition curves for a
number of compounds (EP 171, EP 031, STA2, 19-p- chlorophenoxy
PGF201) turned back slightly at highest concentration tested.
Antagonist displacement curves: The rank order of affinity of the
compounds tested was: GR 32191 > AH 23848. Again the log
concentration-inhibition curves of both compounds reversed at higher
concentrations.
Displacement curves for the EPj receptor agonist, AH 6809: AH 6809
caused a maximum inhibition of specific binding of 20% at 25 pM, the
curve then turned back dramatically, giving counts of 200% of the
control maximum binding at 250 |iM.
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Figure 5.2: Inhibition of [125I]-PTA-OH binding to human
platelets by (a) TP-receptor agonists and (b) TP-receptor
antagonists (means of 4 expts). (bars represent the s.e.m)
log [displacer] (M)
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The vessel was highly sensitive to U 46619, which had an EC50 of ~6 nM.
Both STA2 and EP 171 contracted the preparation, the EMR values were
0.26 and 0.0217 respectively (Fig 5.3). The response to EP 171 was very
slow, the lower doses taking 40-50 minutes to reach a stable level of tone.
The log concentration-response curve of U 46619 was subject to a
parallel rightward shift in the presence of 10 pM GR 32191 (Fig 5.4),
consistent with a pA2 of 7.22 ± 0.10.
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Figure 5.3: Log concentration-response curves for contraction
of the rabbit jugular vein by EP 171, STA2 and U 46619





Figure 5.4: Effect of GR 32191 (10|iM) on the log concentration-
response curve of U 46619 in the rabbit jugular vein




The IC50 value of 69 nM obtained for displacement of [125I]-PTA-OH
binding by U 46619 is comparable to that obtained by Mais et al (1985) (84
nM), Narumiya et al (1986) (125 nM) and Halushka et al (1987) (140nM).
The data in Table 5.1 and 5.2 shows that the rank order of potency of a
series of agonists and antagonists as displacing agents correlates well
with their potency in the platelet. A similar correlation was
demonstrated with a different series of antagonists by Halushka et al
(1987).
The agonist ranking (Table 5.3) for EP 171, STA2 and U 46619 is the
same as that obtained on measuring the potency of these compounds as
contractile agents in various smooth muscle preparations (Jones at al,
1989) and the rabbit jugular vein. Similarly, the Ki values obtained for
the antagonists, GR 32191 and AH 23848 correlate with those obtained in
the vasculature (Lumley et al, 1987; Brittain et al, 1985). Thus, the data
present no evidence that the TP receptors on the platelet differ from
those in the vasculature.
There are a number of possible reasons why the true Kj of some of the
prostanoids may be lower than that measured in ligand binding
experiments. Firstly, a number of the compounds used (EP 171, EP 031,
16-p-chlorophenoxy PGF2a, AH 23848) are racemic and it is possible that
only one enantiomer competes effectively with the radioligand in the
binding assay. It is notable that it has previously been shown (Sprague
et al, 1985) that in the case of the parent compound the isomer formally
related to PGH2/TXA2 is -100 fold more active than the mirror image as
an activator of platelets. Secondly, there may be a reduction in the
initial free concentration of the displacing agent due to TP receptor
binding. For example, assuming the platelet has 1700 TP receptors
(Armstrong et al, 1983), the concentration of TP receptors will be about
0.7 nM. At the IC50 for the compound the concentration of receptors in
the free and bound form will be equal (i.e 0.35 nM) hence, at the IC50
value of 1.45 nM (assuming only one enantiomer is active) the active
species of EP 171 will be reduced to about 1 nM. This will only affect
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Table 5.1: Comparison of the potency of TP receptor agonists in terms
of shape change production and inhibition of [125j]-PTA-OH binding
in human washed platelets (mean of 4-6 expts.).(± s.e.m)
Agonist EC50 for shape Inhibition of [125I]-PTA-OH
change: (nM) binding: kj (nM)
ep 171 0.065 ± 0.011 * 2.9 ± 0.4
ep 031 0.55 ± 0.08 * 11 ± 1.0
16-p-Chlorophenoxy-
co-tetranor-ll-deoxy pgf20c 2.7 ± 0.6 * 23 ± 14
sta2 1.8 ± 0.4 ** 27 ± 4
u 46619 5.4 ± 0.9 * 69 ± 14
ICI79939 27 ± 8 * 440 ± 32
* Jones et al (1989)
**Lawrence et al (1988)
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Table 5.2: Comparison of the potency of TP receptor antagonists in terms
of inhibition of aggregation and inhibition of [125I]-PTA-OH binding in
washed human platelets (mean of 4-6 expts.).
Antagonist Inhibition of platelet Inhibition of [125j].pTA-OH
aggregation: binding:
Kd t (nM) Ki (nM)
GR 32191 1.7 ± 0.2 * 4.6 ± 0.7
AH 23848 5.4 ± 1.1 * 8.8 ± 1.0
* Lawrence et al (1988)
t Kd = antilog pA2 vs U 46619 platelet aggregation
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high potency compounds, as the initial free concentration of less potent
displacing agents would be reduced by less than 10%. The of InM for
EP 171 may account for its slow onset of action on platelets. For
example, if the association rate constant, ki is lxlO7 M-^-s-1 and the
dissociation rate constant k2 is 0.01s-1 (from of InM) then at a
concentration of 0.05 nM the calculated occupation half time is 45
seconds. The measured half time of onset of shape change for EP 171
(Jones et al, 1989) is 38 ± 3 seconds and for U 46619, 9.4 ± 0.4 seconds.
The IC50 values for the agonists obtained in the ligand binding assay are
significantly higher (10-20 fold) than the EC50 values for inducing shape
change, while the Ki values for antagonists are only slightly (~2 fold)
higher than those obtained for inhibition of platelet aggregation. A
similar difference in IC50 values obtained by radioligand binding and
EC50 for platelet aggregation was observed by Halushka et al (1987).
The existence of spare receptors would have predictable consequences
for the comparison of binding and functional data for agonists. If spare
receptors are present, the biological response could still be a linear
function of the number of receptors occupied, but the response would be
maximal when the number of receptors occupied is less than the total
number of receptors by the number of spare receptors. In this case the
biological response for agonists is platelet shape change and it has
previously been shown (Armstrong et al, 1983) that only approximately
5% of receptors are occupied by U 46619 at the EC50. Hence, the
concentration if ligand that elicits a half maximal response in the
radioligand binding experiment (i.e inhibits 50% of [125I]-PTA-OH
specific binding) will be considerably higher than the EC50 measured
biologically.
It is notable that the Ki values obtained for the antagonists, GR 32191
and AH 23848 obtained from the ligand binding study compare well with
those obtained functionally. In the case of antagonists the biological
response is inhibition of a full aggregation wave of U 46619, thus, the
agonist receptor occupancy may be near maximal and the proportion of
spare receptors considerably lower than that present at the EC50 level
for shape change. Hence, one would expect the Ki values for the
antagonists obtained in the radioligand binding experiment to
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correspond more closely to those obtained biologically. Similar results
have been reported in studies of both opioid and adrenergic receptors
(Tallarida, 1988): Kj values for agonists obtained in functional studies
were consistently 1-2 log emits lower than those obtained from binding
studies, in contrast, for antagonists the two values were very similar.
However, the author explains these findings in terms of a two site
receptor model. In this model the agonist binding converts the receptor
to a second state for which agonists have a considerably lower affinity
and produces little response on binding. Antagonists, however, have
equal affinity for both states.
The finding that the EPi receptor antagonist, AH 6809 displaces [125I-
PTA-OH agrees with data showing that this compound inhibits U 46619-
induced human platelet aggregation with a pA2 of 4.4 (Kerry and
Lumley, 1988). However, the Ki cannot be estimated due to the dramatic
turning back of the concentration-response curve at concentrations of
20-200 |iM.
The data have not been analysed using the Hill equation due to the
tendency of the binding curves of a number of displacing agents (both
agonists and antagonist) to reverse slightly with increasing
concentration. It is not clear whether this phenomenon is related to the
more marked belling of the curve of AH 6809. There is no obvious
explanation for this effect. It is possible that the presence of high
concentrations of displacing agents unmasks additional binding sites
for the radioligand.
Rabbit Jugular Vein
Investigation of the contractile action of EP 171 and STA2 in the rabbit
jugular vein (Table 5.3) shows that the activity in terms of EMR (us U
46619) and absolute potency compare with those obtained in other
smooth muscle systems (Jones et al,1989). However, the pA2 value (7.2)
for GR 32191 appears to be considerably lower than those previously
reported for the compound (Table 5.4). It seems that the RJV is similar
to other rabbit tissue (both platelet and vasculature) in having a low
sensitivity to TP receptor antagonists but not agonists (Tymkewcz et al,
1989). It is notable that BM 13.177 has been shown to have similar
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Table 5.3 : Comparison of the agonist potencies of EP 171, STA2 and
U 46619 at TP receptors in the rabbit jugular vein with those of other
smooth muscle preparations (mean of 4-6 expts).
EC50 for Equieffective molar ratio (U46619 = 1)
Preparation EP171 (pM) EP171 STA2
Rabbit aorta 138 0.0136 ± 0.0025 * 0.23 ± 0.06*
Rat aorta 45 0.0094 ± 0.0006 * 0.15 ± 0.02*
Pig pulmonary artery 70 0.0093 ± 0.0008 * 0.21 + 0.03*
Dog saphenous vein 120 0.0302 ± 0.0034 * 0.30 ± 0.05*
Guinea-pig trachea 57 0.0096 ± 0.0012 * 0.35 ± 0.04*
Rabbit jugular vein 125 0.0217 ± 0.0047 0.26 ± 0.06
* Jones at al (1989)
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Table 5.4: Comparison of the pA2 values obtained for GR 32191 and
AH 23848 in the rabbit jugular vein with that obtained in other







GR 32191 AH 23848
8.2 * 7.7 **
8.7 *
y g * 7 9**
7.22 ± 0.1
* Lumley et al (1987)
** Brittain et al (1985)
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activity in rabbit tissues (aorta and platelets) to those of other species
(Tymkewcz and Jones, unpublished data). Giles at al (1989) found that
the pKfi (6.01 ± 0.10) of this blocker in the rabbit jugular vein was
similar to that obtained in both the rabbit aorta and human platelet.
The experimental finding of equal pA2 values of an antagonist
measured against two different agonists is taken to indicate that the
agonists are binding to the same receptor site, while different pA2
values indicate that the agonists are acting at different receptors. The
assumption is made that both agonist and antagonist bind to precisely
the same site. However, if the antagonists bind to accessory sites
adjacent to the agonist binding site then different pA2 values may be
obtained despite identical agonist binding sites (see Raffa et al, 1989).
This would arise in the case of multiple antagonist accessory binding
sites or with multiple subtypes of the antagonist receptor. Such a
situation may exist with TP receptors: the antagonist binding site in the
rabbit may differ from that found in other species. In addition, the
findings of Mais et al (1985a,c ; 1988) showing a different rank order of
potency for 13-azapinane TP receptor antagonists in the platelet and
vasculature of humans and dogs suggest that the binding sites in the
two systems may differ.
Similar observations have been made in other receptor systems. In the
5HT system the data obtained with agonists in various isolated
preparations is not consistent with antagonist data (Leff and Martin,
1988). While the affinity values for 5HT are all found to be within a
relatively narrow range, there is a wide variation (200 fold) in the
antagonist affinity measurements. Also, antagonists of the histamine,
Hi and dopamine, Di receptor show a wide structural diversity such
that they have been classified on the basis of chemical subgroups, and it
has been proposed that they interact with different areas of the
transmembrane section of one agonist receptor molecule (Ariens, 1987).
It could, of course, be argued that the range of TP receptor agonists
tested to date is too small and by chance we have selected those which
show the smallest differences. However, the difficulties associated with
184
agonists such as EP 171 may discourage the experimenter from a much
larger screening process.
We have demonstrated, however, that both the TP receptor antagonists
and agonists displace [125I]-PTA-OH binding to human platelets. It is
notable that Narumiya et al (1986) failed to demonstrate specific binding
of [125I]-PTA-OH to rabbit platelets. It would be interesting to study the
binding of a radiolabeled agonist to rabbit platelets and determine if
both agonists and antagonists displace the compound. EP 171 may be
useful in a study of this nature although the radioligand would have to
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